{"title": "Manifestaciones neurol\u00f3gicas asociadas a la vacuna contra COVID-19", "author": "R Alonso Castillo; J C Mart\u00ednez Castrillo", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554338/", "hostname": "ncbi.nlm.nih.gov", "description": "La enfermedad por coronavirus 2019 (COVID-19) se ha propagado de forma r\u00e1pida, dando lugar a una situaci\u00f3n de pandemia, con importante morbimortalidad. En este contexto han surgido un amplio n\u00famero de vacunas para tratar de hacer ...", "sitename": "PubMed Central (PMC)", "date": "2022-10-12", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Learn more:\n[PMC Disclaimer](/pmc/about/disclaimer/)| [PMC Copyright Notice](/pmc/about/copyright/) [10.1016/j.nrl.2022.09.005](//doi.org/10.1016%2Fj.nrl.2022.09.005)[Epub ahead of print] [36245941](https://pubmed.ncbi.nlm.nih.gov/36245941)\nManifestaciones neurol\u00f3gicas asociadas a la vacuna contra COVID-19\nNeurological manifestations associated with COVID-19 vaccine\nAssociated Data\n[Supplementary Materials](#) [mmc1.doc](/pmc/articles/PMC9554338/bin/mmc1.doc)(877K)GUID: 16A03806-6788-422B-AAB5-E63D08A85142\nAbstract\nIntroducci\u00f3n\nLa enfermedad por coronavirus 2019 (COVID-19) se ha propagado de forma r\u00e1pida, dando lugar a una situaci\u00f3n de pandemia, con importante morbimortalidad. En este contexto han surgido un amplio n\u00famero de vacunas para tratar de hacer frente a la enfermedad.\nObjetivo\nRevisar los casos reportados de manifestaciones neurol\u00f3gicas tras la aplicaci\u00f3n de las vacunas contra COVID-19, describiendo los hallazgos cl\u00ednicos, anal\u00edticos, de neuroimagen y los resultados de salud.\nM\u00e9todos\nRevisi\u00f3n bibliogr\u00e1fica estructurada en la base de datos PubMed.\nResultados\nEncontramos 86 art\u00edculos, que incluyeron 13.809 pacientes con un amplio espectro de manifestaciones neurol\u00f3gicas asociadas temporalmente con la vacunaci\u00f3n contra COVID-19. La mayor\u00eda ocurrieron en mujeres (63,89%), con una mediana de edad de 50 a\u00f1os. Los eventos adversos publicados con m\u00e1s frecuencia fueron par\u00e1lisis facial de Bell 4.936/13.809 (35,7%), cefalea (4.067/13.809), eventos vasculares cerebrales 2.412/13.809 (17,47%), s\u00edndrome de Guillain-Barr\u00e9 868/13.809 (6,28%), desmielinizaci\u00f3n del sistema nervioso central 258/13.809 (1,86%) y trastorno neurol\u00f3gico funcional 398/13.809 (2,88%). La mayor\u00eda de casos publicados se produjeron en asociaci\u00f3n temporal con la vacuna Pfizer (BNT162b2), seguida de la vacuna de AstraZeneca (ChAdOX1 nCoV-19).\nConclusiones\nCon los datos existentes actualmente no es posible establecer una relaci\u00f3n de causalidad entre estos eventos adversos y las vacunas contra la COVID-19, ni calcular la frecuencia de aparici\u00f3n de estos trastornos. Sin embargo, es necesario que los profesionales de la salud est\u00e9n familiarizados con estos eventos, facilitando su diagn\u00f3stico y tratamiento tempranos. Son necesarios grandes estudios epidemiol\u00f3gicos controlados para establecer una posible relaci\u00f3n causal entre la vacunaci\u00f3n contra la COVID-19 y los eventos adversos neurol\u00f3gicos.\nAbstract\nIntroduction\nCoronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease.\nObjective\nTo review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes.\nMethods\nWe carried out a review through bibliographic searches in PubMed.\nResults\nWe found 86 articles, including 13,809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell's palsy 4936/13809 (35.7%), headache (4067/13809), cerebrovascular events 2412/13809 (17.47%), Guillain-Barr\u00e9 syndrome 868/13809 (6.28%), central nervous system demyelination 258/13809 (1.86%) and functional neurological disorder 398/13809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1 nCoV-19).\nConclusions\nIt is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events.\nIntroducci\u00f3n\nEl nuevo SARS-CoV-2, causante de la enfermedad por coronavirus 2019 (COVID-19), se ha propagado r\u00e1pidamente dando lugar a una pandemia, con un impacto devastador en la salud p\u00fablica, la econom\u00eda mundial y la esfera social\n[1](#bib0495), [2](#bib0500). En este contexto se ha llevado a cabo un esfuerzo internacional sin precedentes para desarrollar vacunas eficaces y seguras contra COVID-19. Actualmente est\u00e1n disponibles varias vacunas para las que numerosos pa\u00edses han concedido autorizaciones de uso de emergencia [1](#bib0495), [3](#bib0505).\nLas vacunas BNT162b2 (Pfizer y BioNTech) y mRNA-1273 (Moderna) son vacunas basadas en ARNm. La vacuna ChAdOx1 (Oxford y AstraZeneca) utilizan la tecnolog\u00eda de vector viral no replicante de adenovirus, as\u00ed como las vacunas Ad26.COV2.S (Johnson & Johnson), Convidecia\u00ae y Sputnik-V\u00ae. Las vacunas de Sinovac y de Sinopharm (BBIBP-CorV) utilizan virus inactivados. La \u00fanica vacuna disponible de subunidades proteicas es la NVX-CoV2373 (Novavax)\n[1](#bib0495), [4](#bib0510), [5](#bib0515).\nEl programa de vacunaci\u00f3n contra COVID-19 brinda esperanzas para hacer frente a la pandemia actual. Sin embargo, las vacunas no est\u00e1n exentas de efectos adversos, y es importante identificar y cuantificar estos posibles riesgos. El hecho de que se llevase a cabo un proceso acelerado de desarrollo ha hecho surgir el temor de que se hubiera comprometido su seguridad, de forma que ha pasado a constituir un tema de preocupaci\u00f3n para la opini\u00f3n p\u00fablica\n[4](#bib0510). En los ensayos cl\u00ednicos aleatorizados de las vacunas contra el SARS-CoV-2 se obtuvieron datos tranquilizadores de eficacia y seguridad; sin embargo, estos no tuvieron suficiente poder para detectar eventos adversos muy poco frecuentes y, tras su autorizaci\u00f3n, se est\u00e1n informando una amplia variedad complicaciones neurol\u00f3gicas [6](#bib0520).\nLos ensayos cl\u00ednicos aleatorizados de la vacuna Oxford-AstraZeneca (ChAdOX1 nCoV-19) informaron de 3 casos de mielitis transversa en el grupo de la vacuna, entre los 11.636 participantes incluidos\n[7](#bib0525). Solo un caso se crey\u00f3 finalmente relacionado con la vacunaci\u00f3n. Los ensayos de las vacunas ARNm de Moderna (mRNA-1273) y Pfizer/BioNTech (BNT162b2) [8](#bib0530), [9](#bib0535) informaron de 7 casos de par\u00e1lisis facial de Bell en 37.000 vacunados. El ensayo de la vacuna de Janssen Ad26.COV2.S [10](#bib0540) inform\u00f3 de 3 casos de par\u00e1lisis de Bell en el grupo de la vacuna, uno de s\u00edndrome de Guillain-Barr\u00e9 (SGB) en el grupo vacunado y otro en el grupo placebo, y un episodio de radiculitis braquial. Los eventos tromboemb\u00f3licos venosos fueron m\u00e1s frecuentes en el grupo vacunado, uno de los cuales fue un evento emb\u00f3lico venoso cerebral acompa\u00f1ado de trombocitopenia [3](#bib0505), [11](#bib0545).\nLa mayor parte de los efectos adversos neurol\u00f3gicos graves tras las vacunas contra COVID-19 se informan de manera anecd\u00f3tica, y su incidencia real se desconoce\n[12](#bib0550). El objetivo de este estudio fue tratar de definir el espectro de manifestaciones neurol\u00f3gicas informadas tras la vacunaci\u00f3n contra COVID-19, describiendo las manifestaciones publicadas en la literatura.\nMaterial y m\u00e9todos\nEsta revisi\u00f3n se llev\u00f3 a cabo de acuerdo con las pautas de la declaraci\u00f3n PRISMA\n[13](#bib0555) (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Realizamos b\u00fasquedas bibliogr\u00e1ficas en PubMed entre el 08/01/2022 y el 21/01/2022, utilizando los siguientes t\u00e9rminos en las combinaciones \u00abY\u00bb y \u00abO\u00bb: \u00abCOVID-19 vaccine\u00bb, \u00abCOVID-19 vaccines\u00bb, \u00abSARS-CoV-2 vaccine\u00bb, \u00abSARS-CoV-2 vaccines\u00bb, \u00abneurological manifestations\u00bb, \u00abneurologic manifestations\u00bb, \u00abneurological symptoms\u00bb, \u00abneurologic symptoms\u00bb y \u00abneurology\u00bb. La estrategia de b\u00fasqueda se detalla en la ( [Tabla 1S del material suplementario)](#sec0140). Se examinaron los t\u00edtulos y res\u00famenes de los art\u00edculos obtenidos mediante b\u00fasqueda bibliogr\u00e1fica para valorar su inclusi\u00f3n. Se eliminaron los resultados duplicados.\nSe incluyeron estudios publicados y pre-publicaci\u00f3n que: 1) informaron al menos de un caso de cualquier manifestaci\u00f3n neurol\u00f3gica de nueva aparici\u00f3n asociada temporalmente con la vacunaci\u00f3n por SARS-CoV-2 en humanos, no explicada por otra etiolog\u00eda; 2) incluyeron sujetos vacunados contra COVID-19 con cualquiera de las vacunas disponibles, y 3) publicados en ingl\u00e9s. Los art\u00edculos incluidos se revisaron a texto completo.\nLos estudios se excluyeron ante alguna de las siguientes condiciones: 1) art\u00edculos de revisi\u00f3n, y 2) correspondencia o comunicaciones breves a excepci\u00f3n de que informasen alg\u00fan caso de enfermedad neurol\u00f3gica tras la vacuna contra COVID-19.\nSe extrajeron los siguientes datos: n\u00famero de pacientes que presentaron manifestaciones neurol\u00f3gicas, edad, sexo, complicaci\u00f3n neurol\u00f3gica, tipo de vacuna, dosis, pa\u00eds, intervalo de tiempo entre la vacunaci\u00f3n y la aparici\u00f3n de la manifestaci\u00f3n, presentaci\u00f3n cl\u00ednica, hallazgos de neuroimagen, hallazgos de laboratorio y resultado. Los datos cualitativos se expresaron en porcentajes y n\u00fameros. Los datos cuantitativos se describieron mediante la mediana y el rango.\nResultados\nNuestra b\u00fasqueda arroj\u00f3 271 art\u00edculos, de los cuales 8 fueron excluidos por duplicaci\u00f3n y 263 se cribaron mediante t\u00edtulo y resumen. Se excluyeron 10 art\u00edculos de revisi\u00f3n y 150 art\u00edculos que no informaron casos de manifestaciones neurol\u00f3gicas, y 103 art\u00edculos fueron evaluados a texto completo para su elegibilidad. De estos, 7 fueron excluidos por tratarse de cartas/comentarios que no informaron sobre casos de manifestaciones neurol\u00f3gicas, y 10 por ser art\u00edculos que informaron sobre casos de enfermedad no neurol\u00f3gica. Finalmente, 86 art\u00edculos cumplieron los criterios de inclusi\u00f3n y exclusi\u00f3n, y fueron incluidos en la revisi\u00f3n. El diagrama de flujo para la selecci\u00f3n de estudios se muestra en la\n[figura 1](/pmc/articles/PMC9554338/figure/fig0005/)\n.\nEn total se encontraron 86 art\u00edculos, que incluyeron 13.809 pacientes que mostraron alg\u00fan tipo de manifestaci\u00f3n neurol\u00f3gica. La\n[tabla 1](/pmc/articles/PMC9554338/table/tbl0005/)\nresume los casos de complicaciones neurol\u00f3gicas tras la administraci\u00f3n de la vacuna contra COVID-19 incluidos en la revisi\u00f3n. Existi\u00f3 un predominio femenino (63,89%), con 7.910 casos en mujeres y 4.469 en varones, de los 12.379 en los que se inform\u00f3 el sexo. La mediana de edad fue de 50 a\u00f1os (rango: 19-97).\nTabla 1\n|Complicaci\u00f3n||N.\u00b0||Complicaci\u00f3n||N.\u00b0|\n|Sistema nervioso central|\nEventos vasculares cerebrales\n2.412\n|Sistema nervioso perif\u00e9rico|\nPar\u00e1lisis de Bell\n4.936\n|Hemorragia intracerebral||928||S\u00edndrome de Guillain-Barr\u00e9||868|\n|Trombosis venosa cerebral||706||Trastorno miast\u00e9nico||194|\n|Ictus isqu\u00e9mico||259||S\u00edndrome de Parsonage-Turner||60|\n|Accidente isqu\u00e9mico transitorio||38||Compromiso de otros nervios craneales||12|\n|Desmielinizaci\u00f3n del sistema nervioso central||258||Miositis||3|\n|Esclerosis m\u00faltiple||15||Radiculopat\u00eda||2|\n|Mielitis transversa||11||Otros|\n|Neuritis \u00f3ptica||6|\n|Encefalomielitis aguda diseminada||5||Cefalea||4.067|\n|Neuromielitis \u00f3ptica||3||Trastorno neurol\u00f3gico funcional||398|\n|Signo de la copa de vino||1||Herpes z\u00f3ster||7|\n|Convulsiones||50||Alteraciones del gusto y del olfato||6|\n|Encefalitis posvacunal||5|\n|Meningitis posvacunal||3|\nLas manifestaciones m\u00e1s frecuentemente publicadas fueron par\u00e1lisis de Bell (4.936/13.809; 35,7%), cefalea (4.067/13.809; 29,4%), eventos vasculares cerebrales (2.412/13.809; 17,47%), SGB (868/138.09; 6,28%), desmielinizaci\u00f3n del sistema nervioso central (SNC) (258/13.809; 1,86%) y trastorno neurol\u00f3gico funcional 398/13.809 (2,88%). Otras complicaciones informadas fueron encefalitis (5/13.809), meningitis (3/13.809), convulsiones (50/13809), s\u00edndrome de Parsonage-Turner (60/13.809), compromiso de otros nervios craneales (12/13.809), trastorno miast\u00e9nico (194/13.809), miositis (3/13.809), radiculopat\u00eda (2/13.809), herpes z\u00f3ster (7/13.809) y alteraciones del gusto y del olfato (6/13.809).\nLa vacuna BNT162b2 fue el tipo de vacuna informado con m\u00e1s frecuencia, con 8.820 casos reportados. Se informaron de 3.561 casos de enfermedad neurol\u00f3gica despu\u00e9s de la vacuna ChAdOX1 nCoV-19, 1.256 despu\u00e9s de la vacuna mRNA-1273, 251 despu\u00e9s de la vacuna Ad26.CoV2.S, uno despu\u00e9s de la vacuna de Sinovac, 2 despu\u00e9s de la vacuna Sputnik-V\u00ae, uno despu\u00e9s de la vacuna de Sinopharm (BBIBP-CorV) y uno despu\u00e9s de la vacuna Convidecia\u00ae (AD5-nCOV). La mayor\u00eda de los casos se produjeron tras la primera dosis, 2.991 de los 3.216 que aportaron este dato (93%), mientras que solo 225 tuvieron lugar tras la segunda dosis. Los s\u00edntomas neurol\u00f3gicos se manifestaron tras una mediana de 9 d\u00edas desde la vacunaci\u00f3n (rango: 1-32).\nLos casos de trombosis venosa cerebral (TVC) se informaron con mayor frecuencia tras las vacunas de vectores de adenovirus, al igual que los casos de desmielinizaci\u00f3n del SNC, aunque al desglosar estos por enfermedades, los casos de neuromielitis \u00f3ptica, encefalomielitis aguda diseminada (EMAD) y esclerosis m\u00faltiple (EM) fueron publicados con mayor frecuencia tras las vacunas de ARNm. La enfermedad del sistema nervioso perif\u00e9rico tambi\u00e9n fue m\u00e1s frecuentemente informada tras la administraci\u00f3n de vacunas de vectores virales, salvo la par\u00e1lisis de Bell que se desencaden\u00f3 de forma predominante posteriormente a las vacunas basadas en ARNm.\nLos estudios incluidos se pueden dividir entre aquellos que informaron distintos tipos de complicaciones neurol\u00f3gicas asociadas a la vacuna contra COVID-19, principalmente estudios sobre bases de datos de farmacovigilancia y estudios multic\u00e9ntricos (\n[Tabla 2S del material suplementario](#sec0140)); y aquellos que informaron una misma complicaci\u00f3n neurol\u00f3gica, en su mayor\u00eda informes o series de casos. De esta forma, se incluyeron estudios sobre casos publicados en bases de datos de farmacovigilancia como VigiBase [5](#bib0515) (base de datos global de farmacovigilancia de la Organizaci\u00f3n Mundial de la Salud [OMS]), EudraVigilance [14](#bib0560), [15](#bib0565) (sistema de notificaci\u00f3n de farmacovigilancia de la Agencia Europea del Medicamento), VAERS [16](#bib0570) (Sistema de Notificaci\u00f3n de Reacciones Adversas a las Vacunas de los Centros para el Control y la Prevenci\u00f3n de Enfermedades (CDC) de EE. UU., NIMS [6](#bib0520) (sistema de registro para el programa de vacunaci\u00f3n COVID-19 en Inglaterra), SAEFVIC (sistema de eventos adversos tras la inmunizaci\u00f3n en Victoria, Australia), adem\u00e1s de estudios que incluyeron datos de la Direcci\u00f3n General de Epidemiolog\u00eda del Ministerio de Salud de M\u00e9xico [17](#bib0575), [18](#bib0580), [19](#bib0585) y de los CDC [20](#bib0590). Otros estudios incluidos se trataron de estudios prospectivos multic\u00e9ntricos realizados en varios pa\u00edses (Singapur [21](#bib0595), Reino Unido [22](#bib0600) y Alemania [23](#bib0605)). El resto de art\u00edculos incluidos fueron series de casos o reportes de uno o varios casos.\nSistema nervioso central\nEventos vasculares cerebrales\nLos estudios que reportaron esta complicaci\u00f3n se incluyen en la (\n[Tabla 3S del material suplementario)](#sec0140). Se informaron de 2.412 casos. De los 1.615 casos en los que se document\u00f3 el sexo de los pacientes, 946 ocurrieron en mujeres (58,57%) y 669 en varones (41,42%). La mediana de edad fue de 46 a\u00f1os (rango: 29-67). La mediana de tiempo transcurrido fue de 8 d\u00edas. La mayor\u00eda de estos eventos se desencadenaron tras las vacunas basadas en vector viral no replicante de adenovirus 1.527/2.294 (66,5%). Se informaron de 767/2.294 casos tras las vacunas de ARNm (33,4%). Entre aquellos casos que tuvieron lugar tras la vacuna con vectores virales, la mayor\u00eda se asociaron con trombocitopenia 182/265, valores de d\u00edmero D elevados 72/78, e identificaci\u00f3n de anticuerpos anti-FP4 positivos (73/78). En pacientes a los que se administr\u00f3 la vacuna ARNm, no se obtuvieron estos hallazgos. Al menos el 65,6% (1.222/1.863) de los pacientes fallecieron.\nTrombosis venosa cerebral\nLa TVC fue el evento vascular cerebral m\u00e1s frecuentemente informado. Se report\u00f3 en 706 pacientes, el 74,8% mujeres (217/290) y el 25,17% varones (73/290), con una mediana de edad de 40 a\u00f1os. La mayor\u00eda de los casos se asociaron temporalmente a vacunas de vector viral, con 402/511 casos informados despu\u00e9s de la vacuna ChAdOx-1, 29/511 casos tras la vacuna Ad26.COV2.S 34 y 48/511 casos despu\u00e9s de las vacunas de ARNm. En la mayor\u00eda de los casos asociados a las vacunas de vector viral en los que se informaron datos de laboratorio, la TVC se acompa\u00f1\u00f3 de trombocitopenia (182/264; 68,9%).\nEventos arteriales\nEncontramos 259 casos de ictus isqu\u00e9mico, 928 de hemorragia intracerebral y 38 de accidente isqu\u00e9mico transitorio. Los eventos arteriales en el contexto de la vacunaci\u00f3n contra COVID-19 tambi\u00e9n se asociaron frecuentemente con el fen\u00f3meno de TTIV. Al menos 807/929 (86,8%) pacientes fallecieron.\nDesmielinizaci\u00f3n del sistema nervioso central\nNuestra revisi\u00f3n encontr\u00f3 casos de neuromielitis \u00f3ptica, mielitis transversa, neuritis \u00f3ptica, EM de nuevo diagn\u00f3stico o reca\u00edda y EMAD relacionados temporalmente con la vacuna contra la COVID-19. Identificamos 258 casos de desmielinizaci\u00f3n del SNC (\n[Tabla 4S del material suplementario](#sec0140)), 96/245 en varones (39%) y 149/245 en mujeres (58,6%) con una mediana de tiempo de 9 d\u00edas (rango: 1-30 d\u00edas). La mediana de edad fue de 43 a\u00f1os (rango: 19-88). La mayor parte de los casos ocurrieron tras la vacunaci\u00f3n con ChAdOX1 nCoV-19 (153/236). Se informaron de 78/236 casos con la vacuna BNT162b2, 7/236 con mRNA-1273, 1/236 tras Ad26.CoV2.S, 2/236 tras Sinovac y 1/236 tras Sinopharm.\nMielitis transversa\nEncontramos 11 casos de mielitis transversa, un 66,7% en varones (6/9) y un 33,33% en mujeres (3/9), con inicio de los s\u00edntomas dentro de las 3 primeras semanas. Ocurrieron con mayor frecuencia tras la vacuna ChAdOX1 nCoV-19 (6/11), seguida de BNT162b2 (3/11), Sinopharm (1/11) y Sinovac (1/11). Cinco de los casos fueron informados como mielitis transversa longitudinalmente extensa. El an\u00e1lisis del LCR evidenci\u00f3 pleocitosis en 3 pacientes e hiperproteinorraquia en 7 pacientes. Se obtuvieron anticuerpos anti-AQP4 y anti-glicoprote\u00edna de la mielina de oligodendrocitos (anti-MOG) negativos en 5 pacientes.\nEncefalomielitis aguda diseminada\nSe reportaron 5 casos, 4 mujeres y un var\u00f3n, con mediana de edad de 56 a\u00f1os. Los s\u00edntomas comenzaron dentro del primer mes desde la vacunaci\u00f3n. Tres de los casos se produjeron tras la administraci\u00f3n de vacunas de ARNm, otro tras la vacuna Sinovac y otro tras la vacuna ChAdOX1. Los anticuerpos anti-AQP4 y anti-MOG fueron negativos en los 3 pacientes en los que se estudiaron, as\u00ed como la presencia de bandas oligoclonales. El an\u00e1lisis del LCR mostr\u00f3 pleocitosis en 2/4 casos e hiperproteinorraquia en un caso.\nEsclerosis m\u00faltiple\nSe inform\u00f3 una presentaci\u00f3n similar a la EM en 13 pacientes, de los cuales, 5 contaban con diagn\u00f3stico de EM, mientras que 8 pacientes experimentaron su primer episodio. Hubo un predominio femenino, con 9 casos en mujeres (70%) y 4 en varones (30%). La mediana de edad fue de 41 a\u00f1os (rango: 24-64). Los s\u00edntomas comenzaron entre 1 d\u00eda y un mes desde la administraci\u00f3n de la vacuna. Todos los casos fueron desencadenados por vacunas basadas en ARNm. La RMN encontr\u00f3 nuevas lesiones cerebrales en todos los casos, y nuevas lesiones medulares en 7 casos. En el an\u00e1lisis del LCR se evidenci\u00f3 pleocitosis en 8 de 9 pacientes y bandas oligoclonales en 7 de 9 pacientes.\nEncefalitis posvacunal\nEncontramos 5 casos (\n[tabla 5S del material suplementario](#sec0140)), que ocurrieron dentro de la primera semana tras la vacuna, 2 varones y 3 mujeres; 4 de los cuales se desencadenaron tras la vacuna de ChAdOX1, y uno tras la vacuna ARNm-1273. Entre los s\u00edntomas comunicados se encontraron cefalea, confusi\u00f3n, alucinaciones visuales y t\u00e1ctiles, dificultad de atenci\u00f3n y concentraci\u00f3n, convulsiones, s\u00edndrome opsoclono-mioclono y afasia. Las pruebas de neuroimagen fueron normales en todos los casos y el LCR mostr\u00f3 pleocitosis linfocitaria en todos ellos.\nMeningitis posvacunal\nNuestra revisi\u00f3n identific\u00f3 3 casos de meningitis as\u00e9ptica, todos en mujeres de mediana edad, posteriormente a la vacunaci\u00f3n con BNT162b2 (\n[tabla 5S del material suplementario](#sec0140)). En todos ellos se demostr\u00f3 pleocitosis linfocitaria con hiperproteinorraquia.\nSistema nervioso perif\u00e9rico\nS\u00edndrome de Guillain-Barr\u00e9\nEl SGB fue una complicaci\u00f3n neurol\u00f3gica informada con relativa frecuencia (\n[Tabla 6S del material suplementario](#sec0140)). Encontramos 868 casos, 507 de ellos tras la vacuna ChAdOx1 nCoV-19; 212 con BNT162b2; 77 con mRNA-1273; 59 con Ad26.COV2.S; 4 con CoronaVac\u00ae y uno con Sputnik-V\u00ae. Hubo un predominio masculino, con 474/861 casos en varones (55%) y 387/861 en mujeres (44,94%), tras una mediana de 12 d\u00edas. La mediana de edad fue de 61 a\u00f1os (rango: 25-86).\nDestaca una elevada frecuencia de fenotipos inusuales en la presentaci\u00f3n cl\u00ednica. De 41 casos en los que se describi\u00f3 la cl\u00ednica, 12 presentaron la forma cl\u00e1sica de SGB, 11 presentaron una variante con diplej\u00eda facial, 3 debilidad facial unilateral, 3 tetraparesia, 2 SGB sensitivo, 2 s\u00edndrome de Miller-Fischer y una variante axonal de SGB. El examen del LCR mostr\u00f3 disociaci\u00f3n alb\u00edmino-citol\u00f3gica en 15 pacientes e hiperproteinorraquia en 11 pacientes. La mayor\u00eda mostraron una respuesta parcial y progresiva al tratamiento.\nPar\u00e1lisis facial de Bell\nLa par\u00e1lisis facial de Bell fue la enfermedad neurol\u00f3gica m\u00e1s frecuentemente reportada, con 4.936 casos (\n[Tabla 7S del material suplementario](#sec0140)). Fue m\u00e1s frecuente en el sexo femenino, con 1.994 casos en mujeres (60%) y 1.326 en varones (40%). Se inform\u00f3 de forma predominante despu\u00e9s de las vacunas de ARNm; 2.538 se desencadenaron tras la vacuna BNT162b2, 1.136 tras mRNA-1273, 1.107 tras ChAdOx1 nCoV-19, 162 tras Ad26.COV2.S, 13 tras CoronaVac\u00ae, uno tras Sputnik-V\u00ae y uno tras Convidecia\u00ae. Se logr\u00f3 la recuperaci\u00f3n completa con el tratamiento en la mayor\u00eda de los casos.\nNeuralgia amiotr\u00f3fica-s\u00edndrome de Parsonage-Turner\nEncontramos 60 casos de s\u00edndrome de Parsonage-Turner, 41 en mujeres y 17 en varones (\n[tabla 8S del material suplementario](#sec0140)). En 3 de ellos se describi\u00f3 la presentaci\u00f3n cl\u00ednica: 2 casos se manifestaron con dolor y debilidad a nivel proximal en MMSS, mientras que el tercero present\u00f3 par\u00e1lisis y parestesias de inicio agudo en MMII. Los hallazgos de neuroimagen y laboratorio fueron normales.\nAlteraciones del olfato y del gusto\nTodos los casos incluidos se informaron en el art\u00edculo de Lechien et al.\n[24](#bib0610) ( [Tabla 9S del material suplementario](#sec0140)) con 5 casos de disfunci\u00f3n olfatoria y uno de disfunci\u00f3n gustativa entre 2 y 24 d\u00edas posteriores a la vacunaci\u00f3n con las vacunas ChAdOX1 o BNT162b2, en 5 mujeres y un var\u00f3n, adultos j\u00f3venes o de edad media (entre: 25-52 a\u00f1os). Se produjo la resoluci\u00f3n completa del cuadro en todos los casos.\nHerpes z\u00f3ster\nTodos los casos de herpes z\u00f3ster tras la vacunaci\u00f3n contra COVID-19 se desencadenaron tras la vacuna BNT162b2. Se informaron de 7 casos, con predominio femenino (6/7), entre la primera y la tercera semana posteriores a la vacunaci\u00f3n (\n[Tabla 9S del material suplementario](#sec0140)).\nTrastorno neurol\u00f3gico funcional\nLos casos se resumen en la (\n[tabla 9S del material suplementario)](#sec0140). Garc\u00eda-Grimshaw et al. [18](#bib0580) realizaron un estudio en 10.929 pacientes que informaron un efecto adverso posterior a la vacunaci\u00f3n con la primera dosis de la vacuna BNT162b2 en M\u00e9xico, encontrando 354 pacientes que experimentaron s\u00edntomas sensitivos transitorios (3,4%).\nConvulsiones\nEncontramos 50 casos de convulsiones. Ghosh et al.\n[25](#bib0615) informaron el caso de un var\u00f3n de 68 a\u00f1os que a los 4 d\u00edas de recibir la primera dosis de ChAdOX1 comenz\u00f3 con un episodio de p\u00e9rdida de conexi\u00f3n con el medio y alteraci\u00f3n de la conducta. Fue diagnosticado de convulsi\u00f3n de inicio focal no motor con alteraci\u00f3n de la conciencia y anomal\u00edas conductuales epis\u00f3dicas transitorias.\nDiscusi\u00f3n\nLos ensayos c\u00ednicos aleatorizados de las vacunas contra COVID-19 mostraron una frecuencia muy baja de complicaciones neurol\u00f3gicas graves. Sin embargo, estos estudios no tuvieron suficiente poder para detectar efectos adversos muy poco frecuentes, dado el tama\u00f1o de muestra y la duraci\u00f3n limitada y tras la comercializaci\u00f3n de las vacunas cobra un papel clave la monitorizaci\u00f3n a trav\u00e9s de sistemas de farmacovigilancia\n[3](#bib0505).\nA pesar de las devastadoras consecuencias de la pandemia y la disponibilidad de vacunas eficaces, el miedo hacia las vacunas sigue siendo considerable\n[3](#bib0505). Los eventos adversos neurol\u00f3gicos de las vacunas contra COVID-19 pueden implicar una morbimortalidad significativas y constituyen un tema de preocupaci\u00f3n [26](#bib0620). Sin embargo, la asociaci\u00f3n temporal entre la vacunaci\u00f3n y los eventos adversos no implica necesariamente causalidad. En pacientes que muestren s\u00edntomas neurol\u00f3gicos tras recibir la vacuna debe llevarse a cabo un diagn\u00f3stico diferencial exhaustivo, aunque es preciso tener presente la vacunaci\u00f3n como un posible factor etiol\u00f3gico.\nLa frecuencia de complicaciones neurol\u00f3gicas graves asociadas a estas vacunas parece ser muy baja si se compara con el impacto de la propia enfermedad y, seg\u00fan la informaci\u00f3n actual disponible, los beneficios de la vacunaci\u00f3n superan los potenciales riesgos\n[1](#bib0495), [12](#bib0550), [27](#bib0625), [28](#bib0630). El elevado n\u00famero de casos de infecci\u00f3n por COVID-19 a nivel mundial y de muertes reportadas ponen de manifiesto la importancia del programa de vacunaci\u00f3n, que ha mostrado una muy alta eficacia.\nRespecto a los resultados obtenidos en esta revisi\u00f3n, la edad de presentaci\u00f3n y el predominio femenino fueron congruentes con estudios previos\n[1](#bib0495), [2](#bib0500), [4](#bib0510), [27](#bib0625). El tiempo transcurrido desde la administraci\u00f3n de la vacuna fue tambi\u00e9n similar al encontrado en estudios anteriores, ocurriendo la mayor\u00eda de estos efectos adversos entre una y 4 semanas desde la vacunaci\u00f3n [2](#bib0500), [29](#bib0635). La vacuna informada con m\u00e1s frecuencia fue la de Pfizer (BNT162b2), lo que podr\u00eda haber estado influido por el hecho de que el estudio que cont\u00f3 con un mayor n\u00famero de pacientes fue el de Garc\u00eda-Grimshaw et al. [18](#bib0580), con 4.258 pacientes vacunados con BNT162b2.\nPatone et al.\n[6](#bib0520) investigaron los ingresos hospitalarios por complicaciones neurol\u00f3gicas desencadenadas tras la primera dosis de las vacunas ChAdOx1 CoV-19 (n = 20.417.752) y BNT162b2 (n = 12.134.782), y tras un test de SARS-CoV-2 positivo (n = 2.005.280) en esta misma poblaci\u00f3n vacunada. Se observ\u00f3 un mayor riesgo de ingreso hospitalario por ictus hemorr\u00e1gico en quienes que recibieron la vacuna BNT162b2, y un mayor riesgo de ingreso por SGB, par\u00e1lisis de Bell y trastornos miast\u00e9nicos en receptores de la vacuna ChAdOxIn nCoV-19. Aunque encontraron un mayor riesgo de complicaciones neurol\u00f3gicas en los vacunados contra COVID-19, identificaron un aumento mucho mayor en el riesgo de todos los resultados neurol\u00f3gicos despu\u00e9s de una prueba SARS-CoV-2 positiva.\nUn estudio prospectivo en 704.003 receptores de la primera dosis de la vacuna BNT162b2 en M\u00e9xico\n[17](#bib0575) encontr\u00f3 que un 65,1% de los efectos adversos fueron neurol\u00f3gicos. Los eventos neurol\u00f3gicos no graves ocurrieron en menos del 1%, y los graves en solo un 0,005%. Sin embargo, de los eventos graves, el 52% fueron neurol\u00f3gicos. La mayor\u00eda de los pacientes experimentaron una recuperaci\u00f3n completa en d\u00edas o semanas, sin aparici\u00f3n de secuelas, lo que parece indicar un desencadenante inflamatorio agudo y transitorio. Recientemente se ha publicado un art\u00edculo fuera del periodo analizado, en el que se comunica un 30% m\u00e1s de EA de los que encontrados en nuestro estudio [30](#bib0640).\nUna de las complicaciones de la vacuna COVID-19 que ha suscitado mayor preocupaci\u00f3n son los eventos vasculares cerebrales, reportados principalmente en mujeres en edad f\u00e9rtil, despu\u00e9s de la administraci\u00f3n de vacunas de vectores virales\n[1](#bib0495). Una caracter\u00edstica fundamental de los eventos vasculares cerebrales reportados tras la vacunaci\u00f3n contra el SARS-CoV-2 es que frecuentemente se asocian al fen\u00f3meno de trombocitopenia tromb\u00f3tica inducida por la vacuna (TTIV). Este tiene caracter\u00edsticas que lo asemejan a la trombocitopenia inducida por heparina, con la presencia de anticuerpos contra el factor plaquetario 4 (FP4) [12](#bib0550), [20](#bib0590), [28](#bib0630).\nLos casos de trombosis de senos venosos cerebrales (TSVC) secundarios a las vacunas contra el SARS-CoV-2 se dividen en TSVC en el contexto de TTIV, en relaci\u00f3n con las vacunas basadas en vectores de adenovirus, y TSVC sin caracter\u00edsticas de TTIV, reportados posteriormente a cualquier tipo de vacuna. En la TTIV se identifican anticuerpos anti-FP4 que desencadenan la activaci\u00f3n plaquetaria\n[12](#bib0550), [20](#bib0590), [28](#bib0630).\nEn l\u00ednea con lo observado en esta revisi\u00f3n, la TSVC por TTIV suele ocurrir entre una y 2 semanas despu\u00e9s de la primera dosis de la vacuna de vector viral. Los datos t\u00edpicos de laboratorio incluyen un recuento de plaquetas disminuido (< 100 \u00d7 10\n[9](#bib0535)/l), d\u00edmero D elevado y presencia de anticuerpos anti-FP4 [27](#bib0625), [28](#bib0630), [31](#bib0645).\nKrzywicka et al.\n[14](#bib0560) analizaron los datos cl\u00ednicos de 213 casos de TSVC tras la vacuna COVID-19 notificados a la Agencia Europea del Medicamento y los compararon con un grupo control de casos de TSVC previos a la pandemia. El estudio mostr\u00f3 que la TSVC que ocurre despu\u00e9s de la vacunaci\u00f3n con ChAdOx1 nCov-19 tiene un perfil cl\u00ednico distinto y caracter\u00edstico: se asoci\u00f3 con trombocitopenia y anticuerpos anti-FP4 positivos, se acompa\u00f1\u00f3 frecuentemente de otros eventos tromb\u00f3ticos venosos y mostr\u00f3 altas tasas de mortalidad. Los casos de TSVC informados tras la aplicaci\u00f3n de vacunas de ARNm fueron similares a los casos previos a la pandemia.\nEl hecho de que las caracter\u00edsticas cl\u00ednicas de los casos de TSVC que surgen despu\u00e9s de las vacunas de vectores virales sean espec\u00edficas, la identificaci\u00f3n de un mecanismo fisiopatol\u00f3gico, junto con la secuencia temporal coherente, respaldan una posible relaci\u00f3n de causalidad. Adem\u00e1s, el riesgo importante de mortalidad de esta complicaci\u00f3n pone de manifiesto la importancia del diagn\u00f3stico y tratamiento tempranos\n[15](#bib0565), [20](#bib0590), [28](#bib0630).\nSe sospecha que la vacunaci\u00f3n contra COVID-19 podr\u00eda provocar una respuesta inflamatoria inmunomediada, pudiendo desencadenar fen\u00f3menos de autoinmunidad\n[29](#bib0635), [32](#bib0650). La desmielinizaci\u00f3n suele tener una causa autoinmune subyacente. El mecanismo exacto de desmielinizaci\u00f3n aguda tras las vacunas contra COVID-19 sigue sin comprenderse, existiendo varias teor\u00edas. Una de ellas sugiere que se basa en el fen\u00f3meno de mimetismo molecular. Otro factor que se plantea es el papel inmun\u00f3geno de los adyuvantes que componen algunas vacunas [2](#bib0500), [33](#bib0655). Un tercer posible mecanismo estar\u00eda relacionado con respuestas de c\u00e9lulas T y B y una activaci\u00f3n \u00abby-stander\u00bb de linfocitos autorreactivos latentes [2](#bib0500).\nNuestra revisi\u00f3n obtuvo un 60% de casos ocurridos en mujeres, con una mediana de edad de 42 a\u00f1os. La mayor\u00eda de los casos ocurrieron tras la vacunaci\u00f3n con ChAdOX1 nCoV-19. Una revisi\u00f3n sistem\u00e1tica de los casos de desmielinizaci\u00f3n del SNC reportados tras la vacunaci\u00f3n contra COVID-19, encontr\u00f3 datos similares a estos\n[2](#bib0500). Reuni\u00f3 32 casos con predominio femenino (68,8%) y una mediana de edad de 44 a\u00f1os. Sin embargo, las vacunas basadas en ARNm dieron lugar a un mayor n\u00famero de s\u00edndromes desmielinizantes, seguidas de las vacunas de vectores virales.\nIdentificamos casos de neuromielitis \u00f3ptica, mielitis transversa, neuritis \u00f3ptica, EM y EMAD en relaci\u00f3n temporal con la vacunaci\u00f3n contra el SARS-CoV-2. Se trata de afecciones relativamente poco frecuentes, y los casos asociados a la vacuna son todav\u00eda m\u00e1s raros. La buena respuesta de estos pacientes al tratamiento inmunosupresor parece indicar una reacci\u00f3n inmune transitoria\n[34](#bib0660). Permanece sin aclararse si la vacuna podr\u00eda ser causa directa de las complicaciones autoinmunes o solo las induce en pacientes con autoinmunidad previamente asintom\u00e1tica [29](#bib0635), [35](#bib0665).\nEncontramos un n\u00famero considerable de casos de SGB en relaci\u00f3n temporal con la vacunaci\u00f3n contra el SARS-CoV-2, especialmente con la vacuna de vector viral. Existen informes de este s\u00edndrome tras otros tipos de vacunas, aunque \u00fanicamente se ha logrado probar una asociaci\u00f3n peque\u00f1a pero estad\u00edsticamente significativa de aumento del riesgo tras la vacunaci\u00f3n contra la influenza\n[36](#bib0670), [37](#bib0675), [38](#bib0680), [39](#bib0685). Es particularmente interesante el hecho de que muchos de los casos de SGB publicados tras la vacunaci\u00f3n contra COVID-19 se presentaron como una variante con debilidad bifacial. Esta presentaci\u00f3n parece caracter\u00edstica del SGB en el contexto de la vacunaci\u00f3n contra COVID-19, lo que, junto con la observaci\u00f3n frecuente de otras variantes raras, respalda la sospecha de una relaci\u00f3n de causalidad. El SGB asociado a la vacuna contra el SARS-CoV-2 puede mostrar datos at\u00edpicos de laboratorio, como ausencia de anticuerpos antigangli\u00f3sidos [40](#bib0690), [41](#bib0695).\nOsowicki et al.\n[42](#bib0700) observaron un exceso de casos de SGB tras la vacunaci\u00f3n con ChAdOx1 y BNT162b2 en Australia en comparaci\u00f3n con los casos esperados. Min et al. [43](#bib0705) revisaron los casos reportados de SGB. Todos menos uno mostraron fenotipos infrecuentes, como parestesia distal con diplej\u00eda facial o tetraparesia. Los anticuerpos antigangli\u00f3sidos fueron negativos.\nLa par\u00e1lisis de Bell fue el evento neurol\u00f3gico informado con m\u00e1s frecuencia, especialmente en relaci\u00f3n con las vacunas de ARNm, con predominio femenino. Uno de los estudios incluidos en la revisi\u00f3n con mayor tama\u00f1o muestral fue el de Noseda et al.\n[5](#bib0515) que incluy\u00f3 3.320 casos de par\u00e1lisis de Bell.\nUn estudio que analiz\u00f3 la frecuencia de s\u00edndrome de Parsonage-Turner, par\u00e1lisis de Bell y SGB en VigiBase, en pacientes que recibieron la vacuna COVID-19 encontr\u00f3 que la incidencia de neuralgia amiotr\u00f3fica y SGB tras la vacuna fue similar a la observada previamente para otras vacunas virales, pero la par\u00e1lisis de Bell se inform\u00f3 con una frecuencia desproporcionadamente mayor respecto a otras vacunas virales, especialmente en varones mayores de 75 a\u00f1os\n[5](#bib0515). Por el contrario, previamente Sato et al. [16](#bib0570) hab\u00edan publicado un art\u00edculo en el que los casos de par\u00e1lisis de Bell informados mediante la base de datos VAERS, se notificaron de forma significativamente alta para las vacunas BNT162b2 y mRNA-1273, pero fueron comparables a los casos posteriores a la vacunaci\u00f3n contra la influenza previos a la pandemia.\nEsta revisi\u00f3n tiene varias limitaciones. La mayor parte de la literatura disponible se encontr\u00f3 en forma de informes de casos y series de casos sin grupo control, existiendo la posibilidad de infranotificaci\u00f3n de estos efectos adversos, o bien, de notificaci\u00f3n selectiva de los casos m\u00e1s graves. Debido a que la mayor parte de los datos provienen de informes de casos aislados y series de casos, estos deben interpretarse con precauci\u00f3n, y no permiten inferir causalidad, contando \u00fanicamente con la relaci\u00f3n temporal congruente y la plausibilidad biol\u00f3gica. Los art\u00edculos incluidos provinieron de una sola base de datos. Adem\u00e1s, para conocer la frecuencia de efectos adversos tras cada vacuna, solo disponemos de los estudios de farmacovigilancia, donde s\u00ed se conocen los eventos adversos y el n\u00famero de individuos vacunados.\nPor otro lado, el tipo de vacuna tras la que tuvieron lugar las manifestaciones informadas probablemente sea reflejo de su frecuencia de administraci\u00f3n en los distintos territorios, as\u00ed como del perfil de pacientes a los que se administraron. Posiblemente la vacuna de Pfizer haya resultado la m\u00e1s informada al ser la m\u00e1s empleada. Por ello, los datos de manifestaciones neurol\u00f3gicas informados tras cada una de las vacunas no ser\u00edan comparables.\nProbablemente los casos de cefalea no hayan sido publicados como eventos adversos neurol\u00f3gicos, y nuestro estudi\u00f3 s\u00f3lo encontramos algunos casos de cefalea recogidos en estudios de farmacovigilancia, cuando se trat\u00f3 de una de las manifestaciones m\u00e1s frecuentes en los ensayos cl\u00ednicos aleatorizados\n[7](#bib0525), [8](#bib0530), [9](#bib0535), [10](#bib0540), [11](#bib0545).\nConclusiones\nEncontramos un amplio espectro de manifestaciones neurol\u00f3gicas que han sido informadas en relaci\u00f3n temporal con la vacuna contra COVID-19, con hallazgos y presentaciones heterog\u00e9neas. Las manifestaciones encontradas con m\u00e1s frecuencia fueron par\u00e1lisis de Bell, cefalea, eventos vasculares cerebrales, SGB, desmielinizaci\u00f3n del SNC y trastorno neurol\u00f3gico funcional. Sin embargo, no es posible establecer una relaci\u00f3n de causalidad ni calcular la frecuencia de estos trastornos en base a los resultados obtenidos en este estudio.\nLa importancia de estos hallazgos radica en la necesidad de que los profesionales de la salud est\u00e9n familiarizados con estas complicaciones raras, pero potencialmente graves, ya que su diagn\u00f3stico temprano y el inicio r\u00e1pido de un tratamiento adecuado pueden ayudar a lograr un resultado m\u00e1s favorable. Subrayamos la importancia de la vigilancia posterior a la comercializaci\u00f3n de las vacunas para identificar estos eventos adversos infrecuentes y garantizar la seguridad de estas. Son necesarios estudios prospectivos controlados de gran tama\u00f1o para probar o refutar, y cuantificar en su caso la asociaci\u00f3n causal entre estas vacunas y los eventos adversos neurol\u00f3gicos. Es fundamental contextualizar el riesgo en caso de que se confirme la asociaci\u00f3n.\nFinanciaci\u00f3n\nLos autores declaran que no ha habido fuente de financiaci\u00f3n.\nConflicto de intereses\nLos autores declaran que no tienen ning\u00fan conflicto de intereses.\nFootnotes\nAnexoSe puede consultar material adicional a este art\u00edculo en su versi\u00f3n electr\u00f3nica disponible en\n[doi:10.1016/j.nrl.2022.09.005](//doi.org/10.1016/j.nrl.2022.09.005).\nAnexo A. Material adicional\n[Click here to view.](/pmc/articles/PMC9554338/bin/mmc1.doc)(877K, doc)\nBibliograf\u00eda\n[PMC free article](/pmc/articles/PMC8557950/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34719776)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05662-9)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Spectrum+of+neurological+complications+following+COVID-19+vaccination&author=R.K.+Garg&author=V.K.+Paliwal&volume=43&publication_year=2022&pages=3-40&pmid=34719776&doi=10.1007/s10072-021-05662-9&)] [PMC free article](/pmc/articles/PMC8577051/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34839149)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577765)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=A+systematic+review+of+cases+of+CNS+demyelination+following+COVID-19+vaccination&author=I.I.+Ismail&author=S.+Salama&volume=362&publication_year=2022&pages=577765&pmid=34839149&doi=10.1016/j.jneuroim.2021.577765&)] [PMC free article](/pmc/articles/PMC8366487/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34398270)] [ [CrossRef](//doi.org/10.1007%2Fs00415-021-10747-8)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=Interpretation+of+vaccine+associated+neurological+adverse+events:+A+methodological+and+historical+review&author=M.+Cauchi&author=H.+Ball&author=Y.+Ben-Shlomo&author=N.+Robertson&volume=269&publication_year=2022&pages=493-503&pmid=34398270&doi=10.1007/s00415-021-10747-8&)] [PMC free article](/pmc/articles/PMC8250748/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33779985)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=The+potential+neurological+effect+of+the+COVID-19+vaccines:+A+review&author=L.+Lu&author=W.+Xiong&author=J.+Mu&author=Q.+Zhang&author=H.+Zhang&volume=144&publication_year=2021&pages=3-12&pmid=33779985&)] [PMC free article](/pmc/articles/PMC8473382/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34579259)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccines&title=Reporting+of+acute+inflammatory+neuropathies+with+covid-19+vaccines:+Subgroup+disproportionality+analyses+in+vigibase&author=R.+Noseda&author=P.+Ripellino&author=S.+Ghidossi&author=R.+Bertoli&author=A.+Ceschi&volume=9&publication_year=2021&pages=1022&pmid=34579259&)] [PMC free article](/pmc/articles/PMC8629105/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34697502)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Med&title=Neurological+complications+after+first+dose+of+COVID-19+vaccines+and+SARS-CoV-2+infection&author=M.+Patone&author=L.+Handunnetthi&author=D.+Saatci&author=J.+Pan&author=S.V.+Katikireddi&volume=27&publication_year=2021&pages=2144-2153&pmid=34697502&)] [PMC free article](/pmc/articles/PMC7723445/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33306989)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Safety+and+efficacy+of+the+ChAdOx1+nCoV-19+vaccine+(AZD1222)+against+SARS-CoV-2:+An+interim+analysis+of+four+randomised+controlled+trials+in+Brazil+South+Africa,+and+the+UK&author=M.+Voysey&author=S.+Ann&author=C.+Clemens&author=S.A.+Madhi&author=L.Y.+Weckx&volume=397&publication_year=2021&pages=99-111&pmid=33306989&)] [PMC free article](/pmc/articles/PMC7787219/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33378609)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Efficacy+and+Safety+of+the+mRNA-1273+SARS-CoV-2+Vaccine&author=L.R.+Baden&author=H.M.+El+Sahly&author=B.+Essink&author=K.+Kotloff&author=S.+Frey&volume=384&publication_year=2021&pages=403-416&pmid=33378609&)] [PMC free article](/pmc/articles/PMC7745181/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33301246)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Safety+and+Efficacy+of+the+BNT162b2+mRNA+Covid-19+Vaccine&author=F.P.+Polack&author=S.J.+Thomas&author=N.+Kitchin&author=J.+Absalon&author=A.+Gurtman&volume=383&publication_year=2020&pages=2603-2615&pmid=33301246&)] [PMC free article](/pmc/articles/PMC7821985/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33440088)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Interim+Results+of+a+Phase+1-2a+Trial+of+Ad26.COV2.S+Covid-19+Vaccine&author=J.+Sadoff&author=M.+Le+Gars&author=G.+Shukarev&author=D.+Heerwegh&author=C.+Truyers&volume=384&publication_year=2021&pages=1824-1835&pmid=33440088&)] [PMC free article](/pmc/articles/PMC8220996/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33882225)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Safety+and+Efficacy+of+Single-Dose+Ad26.COV2.S+Vaccine+against+Covid-19&author=P.A.+Goepfert&author=C.+Truyers&author=H.+Fennema&author=B.+Spiessens&author=K.+Offergeld&volume=384&publication_year=2021&pages=2187-2201&pmid=33882225&)] [PMC free article](/pmc/articles/PMC8421080/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34507266)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Imaging.&title=Neurological+symptoms+and+neuroimaging+alterations+related+with+COVID-19+vaccine:+Cause+or+coincidence?&author=D.+Goulart+Corr\u00eaa&author=L.A.+Quevedo+Ca\u00f1ete&author=G.A.+Cruz+dos+Santos&author=R.V.+de+Oliveira&author=C.O.+Brand\u00e0o&volume=80&publication_year=2021&pages=348-352&pmid=34507266&)] [PMC free article](/pmc/articles/PMC8005924/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33782057)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ&title=The+PRISMA+2020+statement:+An+updated+guideline+for+reporting+systematic+reviews&author=M.J.+Page&author=J.E.+McKenzie&author=P.M.+Bossuyt&author=I.+Boutron&author=T.C.+Hoffmann&publication_year=2021&pages=372&)] [PMC free article](/pmc/articles/PMC8444640/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34293217)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Post-SARS-CoV-2-vaccination+cerebral+venous+sinus+thrombosis:+An+analysis+of+cases+notified+to+the+European+Medicines+Agency&author=K.+Krzywicka&author=M.R.+Heldner&author=M.+S\u00e1nchez+van+Kammen&author=T.+van+Haaps&author=S.+Hiltunen&volume=28&publication_year=2021&pages=3656-3662&pmid=34293217&)] [PMC free article](/pmc/articles/PMC8652752/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34536256)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Declining+mortality+of+cerebral+venous+sinus+thrombosis+with+thrombocytopenia+after+SARS-2+vaccination&author=A.+Munckhof&author=+Van+De&author=K.+Krzywicka&author=D.+Aguiar&author=M.+S\u00e1nchez&volume=29&publication_year=2022&pages=339-344&pmid=34536256&)] [PMC free article](/pmc/articles/PMC8418051/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34492394)] [ [CrossRef](//doi.org/10.1016%2Fj.ijid.2021.08.071)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Infect+Dis&title=Facial+nerve+palsy+following+the+administration+of+COVID-19+mRNA+vaccines:+Analysis+of+a+self-reporting+database&author=K.+Sato&author=T.+Mano&author=Y.+Niimi&author=T.+Toda&author=A.+Iwata&volume=111&publication_year=2021&pages=310-312&pmid=34492394&doi=10.1016/j.ijid.2021.08.071&)] [PMC free article](/pmc/articles/PMC8213977/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34147649)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Immunol&title=Neurologic+adverse+events+among+704,003+first-dose+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine+in+Mexico:+A+nationwide+descriptive+study&author=M.+Garc\u00eda-Grimshaw&author=S.E.+Ceballos-Liceaga&author=L.E.+Hern\u00e1ndez-Vanegas&author=I.+N\u00fa\u00f1ez&author=N.+Hern\u00e1ndez-Valdivia&volume=229&publication_year=2021&pages=108786&pmid=34147649&)] [PMC free article](/pmc/articles/PMC8554108/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34742595)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Transient+sensory+symptoms+among+first-dose+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine:+A+case-control+study&author=M.+Garc\u00eda-Grimshaw&author=S.E.+Ceballos-Liceaga&author=A.+Michel-Ch\u00e1vez&author=M.+Garc\u00eda-Alanis&author=A.+Cadena-Fern\u00e1ndez&volume=39&publication_year=2021&pages=6975-6979&pmid=34742595&)] [PMC free article](/pmc/articles/PMC8332675/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34358692)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Immunol&title=Guillain-Barr\u00e9+syndrome+is+infrequent+among+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine&author=M.+Garc\u00eda-Grimshaw&author=A.+Michel-Ch\u00e1vez&author=J.M.+Vera-Zertuche&author=J.A.+Galnares-Olalde&author=L.E.+Hern\u00e1ndez-Vanegas&volume=230&publication_year=2021&pages=108818&pmid=34358692&)] [PMC free article](/pmc/articles/PMC8186447/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34116145)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Am+Coll+Cardiol&title=Cerebral+Venous+Sinus+Thrombosis+in+the+U.S.+Population+After+Adenovirus-Based+SARS-CoV-2+Vaccination,+and+After+COVID-19&author=B.+Bikdeli&author=S.+Chatterjee&author=S.+Arora&author=M.+Monreal&author=D.+Jimenez&volume=78&publication_year=2021&pages=408-411&pmid=34116145&)] [PMC free article](/pmc/articles/PMC8511874/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34688190)] [ [CrossRef](//doi.org/10.1016%2Fj.jns.2021.120030)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol+Sci&title=Hospital-based+observational+study+of+neurological+disorders+in+patients+recently+vaccinated+with+COVID-19+mRNA+vaccines&author=J.S.+Koh&author=R.H.M.+Hoe&author=M.H.+Yong&author=H.J.+Chiew&author=Y.+Goh&volume=430&publication_year=2021&pages=120030&pmid=34688190&doi=10.1016/j.jns.2021.120030&)] [PMC free article](/pmc/articles/PMC8346241/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34370972)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Cerebral+venous+thrombosis+after+vaccination+against+COVID-19+in+the+UK:+Multicentre+cohort+study&author=R.J.+Perry&author=A.+Tamborska&author=B.+Singh&author=B.+Craven&author=R.+Marigold&volume=398&publication_year=2021&pages=1147-1156&pmid=34370972&)] [PMC free article](/pmc/articles/PMC8427115/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34288044)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=COVID-19+Vaccine-Associated+Cerebral+Venous+Thrombosis+in+Germany&author=J.B.+Schulz&author=P.+Berlit&author=H.+Diener&author=C.+Gerloff&author=A.+Greinacher&volume=90&publication_year=2021&pages=627-639&pmid=34288044&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/34467793)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nose+Throat+J&title=COVID-19:+Post-vaccine+Smell+Taste+Disorders:+Report+of+6+Cases+Ear&author=J.R.+Lechien&author=A.O.+Diallo&author=B.+Dachy&author=S.D.+Le+Bon&author=A.+Maniaci&publication_year=2021&)] [PMC free article](/pmc/articles/PMC8105133/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34000712)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes+Metab+Syndr+Clin+Res+Rev&title=Focal+onset+non-motor+seizure+following+COVID-19+vaccination:+A+mere+coincidence?&author=R.+Ghosh&author=S.+Dubey&author=D.+Roy&author=A.+Mandal&author=D.+Naga&volume=15&publication_year=2021&pages=1023-1024&)] [PMC free article](/pmc/articles/PMC8548963/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34475124)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Neurologic+Safety+Monitoring+of+COVID-19+Vaccines:+Lessons+from+the+Past+to+Inform+the+Present&author=K.T.+Thakur&author=S.+Epstein&author=A.+Bilski&author=A.+Balbi&author=A.K.+Boehme&volume=97&publication_year=2021&pages=767-775&pmid=34475124&)] [PMC free article](/pmc/articles/PMC8330139/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34365148)] [ [CrossRef](//doi.org/10.1016%2Fj.jns.2021.117607)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol+Sci&title=Vaccine-induced+immune+thrombotic+thrombocytopenia+and+cerebral+venous+sinus+thrombosis+post+COVID-19+vaccination;+A+systematic+review&author=M.+Sharifian-Dorche&author=M.+Bahmanyar&author=A.+Sharifian-Dorche&author=P.+Mohammadi&author=M.+Nomovi&volume=428&publication_year=2021&pages=117607&pmid=34365148&doi=10.1016/j.jns.2021.117607&)] [PMC free article](/pmc/articles/PMC8056834/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33857630)] [ [CrossRef](//doi.org/10.1016%2Fj.bbi.2021.04.006)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Brain+Behav+Immun&title=Cerebral+venous+sinus+thrombosis+and+thrombocytopenia+after+COVID-19+vaccination+-+A+report+of+two+UK+cases&author=P.R.+Mehta&author=S.+Apap+Mangion&author=M.+Benger&author=B.R.+Stanton&author=J.+Czuprynska&volume=95&publication_year=2021&pages=514-517&pmid=33857630&doi=10.1016/j.bbi.2021.04.006&)] [PMC free article](/pmc/articles/PMC8652629/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34668274)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Neurological+autoimmune+diseases+following+vaccinations+against+SARS-CoV-2:+A+case+series&author=L.D.+Kaulen&author=S.+Doubrovinskaia&author=C.+Mooshage&author=B.+Jordan&author=J.+Purrucker&volume=29&publication_year=2022&pages=555-563&pmid=34668274&)] [PMC free article](/pmc/articles/PMC9082459/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35233819)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Neurological+Events+Reported+after+COVID-19+Vaccines:+An+Analysis+of+Vaccine+Adverse+Event+Reporting+System&author=J.A.+Frontera&author=A.A.+Tamborska&author=M.F.+Doheim&author=D.+Garcia-azorin&author=H.+Gezegen&volume=91&publication_year=2022&pages=756-771&)] [PMC free article](/pmc/articles/PMC8344576/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34247246)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=QJM&title=COVID-19+vaccine-associated+acute+cerebral+venous+thrombosis+pulmonary+artery+embolism&author=R.+Wang&author=W.+Chiang&author=H.+Shyu&author=M.+Chen&author=C.+Lin&volume=114&publication_year=2021&pages=506-507&pmid=34247246&)] [PMC free article](/pmc/articles/PMC8426979/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34324214)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Postvaccinal+Encephalitis+after+ChAdOx1+nCov-19&author=F.+Zuhorn&author=T.+Graf&author=R.+Klingebiel&author=W.R.+Sch\u00e4bitz&author=A.+Rogalewski&volume=90&publication_year=2021&pages=506-511&pmid=34324214&)] [PMC free article](/pmc/articles/PMC8653244/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34900001)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Neuroimmunol&title=Optic+neuritis+after+COVID-19+vaccine+application&author=C.+Garc\u00eda-Estrada&author=E.+G\u00f3mez-Figueroa&author=L.+Alban&author=A.+Arias-C\u00e1rdenas&volume=00&publication_year=2021&pages=1-3&)] [PMC free article](/pmc/articles/PMC8506086/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34641797)] [ [CrossRef](//doi.org/10.1186%2Fs12883-021-02427-x)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=Longitudinal+extensive+transverse+myelitis+following+ChAdOx1+nCOV-19+vaccine:+A+case+report&author=W.Y.+Tan&author=A.H.K.+Yusof+Khan&author=M.N.+Mohd+Yaakob&author=A.M.+Abdul+Rashid&author=W.C.+Loh&volume=21&publication_year=2021&pages=395&pmid=34641797&doi=10.1186/s12883-021-02427-x&)] [PMC free article](/pmc/articles/PMC8241205/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34189662)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05427-4)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Watch+out+for+neuromyelitis+optica+spectrum+disorder+after+inactivated+virus+vaccination+for+COVID-19&author=S.+Chen&author=X.+Rui&author=F.+Shuang&author=H.+Jie&author=W.+Zhang&volume=42&publication_year=2021&pages=3537-3539&pmid=34189662&doi=10.1007/s10072-021-05427-4&)] [PMC free article](/pmc/articles/PMC8653182/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34900000)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Neuroimmunol&title=Guillain\u2013Barr\u00e9+syndrome+after+coronavirus+disease+2019+vaccine:+A+temporal+association&author=G.F.+da+Silva&author=C.F.+da+Silva&author=R.E.N.+da+Oliveira&author=F.+Romancini&author=R.M.+Mendes&volume=00&publication_year=2021&pages=1-3&)] [PMC free article](/pmc/articles/PMC8405530/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34484780)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Case+Reports&title=COVID-19+vaccine+causing+Guillain-Barre+syndrome,+a+rare+potential+side+effect&author=A.S.+Matarneh&author=A.H.+Al-battah&author=K.+Farooqui&author=M.+Ghamoodi&author=M.+Alhatou&volume=9&publication_year=2021&pages=e04756&)] [PMC free article](/pmc/articles/PMC8598937/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34789193)] [ [CrossRef](//doi.org/10.1186%2Fs12883-021-02489-x)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=Miller+Fisher+syndrome+following+BNT162b2+mRNA+coronavirus+2019+vaccination&author=Y.+Nishiguchi&author=H.+Matsuyama&author=K.+Maeda&author=A.+Shindo&author=H.+Tomimoto&volume=21&publication_year=2021&pages=452&pmid=34789193&doi=10.1186/s12883-021-02489-x&)] [PMC free article](/pmc/articles/PMC8346349/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34538679)] [ [CrossRef](//doi.org/10.1016%2Fj.jemermed.2021.07.062)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Emerg+Med&title=Guillain-Barr\u00e9+Syndrome+Presenting+as+Facial+Diplegia+after+COVID-19+Vaccination:+A+Case+Report&author=A.+Rossetti&author=G.+Gheihman&author=M.+O\u2019Hare&author=J.M.+Kosowsky&volume=61&publication_year=2021&pages=e141-e145&pmid=34538679&doi=10.1016/j.jemermed.2021.07.062&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/34779385)] [ [CrossRef](//doi.org/10.1016%2Fj.jemermed.2021.07.062)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta+Medica+(Hradec+Kralove)&title=Guillan-Barr\u00e9+Syndrome+after+First+Vaccination+Dose+against+COVID-19:+Case+Report&author=D.+\u010cen\u0161\u010d\u00e1k&author=L.+Ungermann&author=I.+\u0160t\u011btk\u00e1\u0159ov\u00e1&author=E.+Ehler&volume=64&publication_year=2021&pages=183-186&pmid=34779385&doi=10.1016/j.jemermed.2021.07.062&)] [PMC free article](/pmc/articles/PMC8634230/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34848426)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Miller-Fisher+Syndrome+and+Guillain-Barre+Syndrome+overlap+syndrome+in+a+patient+post+Oxford-AstraZeneca+SARS-CoV-2+vaccination&author=Y.L.+Dang&author=A.+Bryson&volume=14&publication_year=2021&pages=e246701&)] [PMC free article](/pmc/articles/PMC8652921/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34528279)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Guillain-Barr\u00e9+Syndrome+in+an+Australian+State+Using+Both+mRNA+and+Adenovirus-Vector+SARS-CoV-2+Vaccines&author=J.+Osowicki&author=H.+Morgan&author=A.+Harris&author=N.W.+Crawford&author=J.P.+Buttery&volume=90&publication_year=2021&pages=856-858&pmid=34528279&)] [PMC free article](/pmc/articles/PMC8349403/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34416410)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577691)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=Sensory+Guillain-Barre+syndrome+following+the+ChAdOx1+nCov-19+vaccine:+Report+of+two+cases+and+review+of+literature&author=Y.G.+Min&author=W.+Ju&author=Y.E.+Ha&author=J.J.+Ban&author=S.A.+Lee&volume=359&publication_year=2021&pages=577691&pmid=34416410&doi=10.1016/j.jneuroim.2021.577691&)]\nReferences\n[PMC free article](/pmc/articles/PMC8420211/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34133027)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am+Event+J+Hematol&title=Cerebral+venous+thrombosis+post+BNT162b2+SARS-CoV-2+vaccination:+mRNA.+black+swan+A&author=B.E.+Fan&author=J.Y.+Shen&author=X.R.+Lim&author=T.M.+Tu&author=C.C.R.+Chang&volume=96&publication_year=2021&pages=E357-E361&)] [PMC free article](/pmc/articles/PMC8140563/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34023956)] [ [CrossRef](//doi.org/10.1007%2Fs00415-021-10599-2)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=Immediate+high-dose+intravenous+immunoglobulins+followed+by+direct+thrombin-inhibitor+treatment+is+crucial+for+survival+in+Sars-Covid-19-adenoviral+vector+vaccine-induced+immune+thrombotic+thrombocytopenia+VITT+with+cerebral+sinus+venous+and+portal+vein+t&author=T.+Graf&author=T.+Thiele&author=R.+Klingebiel&author=A.+Greinacher&author=W.+R\u00fcdiger&volume=268&publication_year=2021&pages=4483-4485&pmid=34023956&doi=10.1007/s00415-021-10599-2&)] [PMC free article](/pmc/articles/PMC8717801/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34244448)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Stroke+Vasc+Neurol&title=Cerebral+venous+sinus+thrombosis+after+19+vaccination+with+a+misleading+first+cerebral+MRI+scan&author=B.+Ikenberg&author=A.F.+Demleitner&author=T.+Thiele&author=B.+Wiestler&author=K.+G\u00f6tze&volume=6&publication_year=2021&pages=e001095&)] [PMC free article](/pmc/articles/PMC8397593/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34461442)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Stroke+Cerebrovasc+Dis&title=Treatment+of+ChAdOx1+nCoV-19+Vaccine-Induced+Immune+Thrombotic+Thrombocytopenia+Related+Acute+Ischemic+Stroke&author=J.+Kenda&author=D.+Lovri\u010d&author=M.+\u0160kerget&author=N.+Milivojevi\u0107&volume=30&publication_year=2021&pages=106072&pmid=34461442&)] [PMC free article](/pmc/articles/PMC8422498/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34513173)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Surg+Neurol+Int&title=A+rare+case+of+vaccine-induced+immune+thrombosis+and+thrombocytopenia+and+approach+to+management&author=R.+Kotal&author=I.+Jacob&author=P.+Rangappa&author=K.+Rao&author=G.+Hosurkar&volume=12&publication_year=2021&pages=408&pmid=34513173&)] [PMC free article](/pmc/articles/PMC8552183/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34706921)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Cerebral+venous+sinus+thrombosis+after+ChAdOx1+vaccination:+The+first+case+of+definite+thrombosis+with+thrombocytopenia+syndrome+from+India&author=B.V.+Maramattom&author=F.M.+Moidu&author=S.+Varikkottil&author=A.A.+Syed&volume=14&publication_year=2021&pages=e246455&)] [PMC free article](/pmc/articles/PMC8112568/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33835768)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med.&title=Thrombosis+and+Thrombocytopenia+after+ChAdOx1+nCoV-19+Vaccination&author=N.H.+Schultz&author=I.H.+S\u00f8rvoll&author=A.E.+Michelsen&author=L.A.+Munthe&author=F.+Lund-Johansen&volume=384&publication_year=2021&pages=2124-2130&pmid=33835768&)] [PMC free article](/pmc/articles/PMC8219289/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34137813)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood+Adv&title=A+case+of+thrombocytopenia+and+multiple+thromboses+after+vaccination+with+ChAdOx1+nCoV-19+against+SARS-CoV-2&author=A.L.T.+Sorensen&author=M.+Rolland&author=J.+Hartmann&author=Z.B.+Harboe&author=C.+Roed&volume=5&publication_year=2021&pages=2569-2574&pmid=34137813&)] [PMC free article](/pmc/articles/PMC8084604/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34323939)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Prothrombotic+immune+thrombocytopenia+after+COVID-19+vaccination&author=A.+Tiede&author=U.J.+Sachs&author=A.+Czwalinna&author=S.+Werwitzke&author=R.+Bikker&volume=138&publication_year=2021&pages=350-353&pmid=34323939&)] [PMC free article](/pmc/articles/PMC8593397/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34783932)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05714-0)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Cerebral+venous+sinus+thrombosis+after+mRNA-based+COVID-19+vaccination&author=Y.+Yagi&author=Y.+Asami&author=M.+Kyoya&author=T.+Yokota&volume=43&publication_year=2022&pages=41-43&pmid=34783932&doi=10.1007/s10072-021-05714-0&)] [PMC free article](/pmc/articles/PMC8046413/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33864750)] [ [CrossRef](//doi.org/10.1016%2FS0140-6736(21)00872-2)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Bilateral+superior+ophthalmic+vein+thrombosis,+ischaemic+stroke,+and+immune+thrombocytopenia+after+ChAdOx1+nCoV-19+vaccination&author=A.+Bayas&author=M.+Menacher&author=M.+Christ&author=L.+Behrens&author=A.+Rank&volume=397&publication_year=2021&pages=e11&pmid=33864750&doi=10.1016/S0140-6736(21)00872-2&)] [PMC free article](/pmc/articles/PMC8250306/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33877737)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Thromb+Haemost&title=Thrombocytopenia+with+acute+ischemic+stroke+and+bleeding+in+a+patient+newly+vaccinated+with+an+adenoviral+vector-based+COVID-+19+vaccine&author=R.A.+Blauenfeldt&author=S.R.+Kristensen&author=S.L.+Ernstsen&author=C.+Christina&author=H.+Kristensen&volume=19&publication_year=2021&pages=1771-1775&pmid=33877737&)] [PMC free article](/pmc/articles/PMC8444739/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34273119)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=Large+hemorrhagic+stroke+after+ChAdOx1+nCoV-19+vaccination:+A+case+report&author=M.L.+M\u00e9lo&author=S.+De&author=D.P.+Lopes&volume=144&publication_year=2021&pages=717-718&pmid=34273119&)] [PMC free article](/pmc/articles/PMC8382847/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34447349)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Front+Neurol&title=Severe+Multiple+Sclerosis+Relapse+After+COVID-19+Vaccination:+A+Case+Report&author=G.T.+Maniscalco&author=V.+Manzo&author=M.E.+di+Battista&author=S.+Salvatore&author=O.+Moreggia&volume=12&publication_year=2021&pages=72-718&)] [PMC free article](/pmc/articles/PMC8567291/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34714721)] [ [CrossRef](//doi.org/10.1080%2F21645515.2021.1971920)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum+Vaccines+Immunother&title=demyelination+in+a+subject+with+cerebellar+ataxia+following+the+first+dose+of+COVID-19+vaccine;+a+case+report&author=O.+Mirmosayyeb&author=S.+Bagherieh&author=V.+Shaygannejad&author=C.N.S.+Acute&volume=17&publication_year=2021&pages=4099-4101&doi=10.1080/21645515.2021.1971920&)] [PMC free article](/pmc/articles/PMC8943383/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34897155)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Intern+Med&title=A+Case+of+Refractory+Longitudinally+Extensive+Transverse+Myelitis+after+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+Vaccination+in+a+Japanese+Man&author=N.+Miyaue&author=A.+Yoshida&author=Y.+Yamanishi&author=S.+Tada&author=R.+Ando&volume=61&publication_year=2022&pages=739-742&pmid=34897155&)] [PMC free article](/pmc/articles/PMC8136261/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34018145)] [ [CrossRef](//doi.org/10.1007%2Fs13760-021-01699-x)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Belg&title=Acute+disseminated+encephalomyelitis+-+like+presentation+after+an+inactivated+coronavirus+vaccine&author=G.+Ozgen&author=K.+Buse&author=C.+Ari&author=C.+Guler&author=M.+Kemal&volume=121&publication_year=2021&pages=1089-1091&pmid=34018145&doi=10.1007/s13760-021-01699-x&)] [PMC free article](/pmc/articles/PMC8223023/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34182207)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577606)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=A+case+of+longitudinally+extensive+transverse+myelitis+following+vaccination+against+Covid-19&author=C.+Pagenkopf&author=M.+S\u00fcdmeyer&volume=358&publication_year=2021&pages=577606&pmid=34182207&doi=10.1016/j.jneuroim.2021.577606&)] [PMC free article](/pmc/articles/PMC8567127/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34735684)] [ [CrossRef](//doi.org/10.1007%2Fs12024-021-00440-7)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Forensic+Sci+Med+Pathol&title=Acute+disseminated+encephalomyelitis+(ADEM)+following+recent+Oxford/AstraZeneca+COVID-19+vaccination&author=F.+Permezel&author=B.+Borojevic&author=S.+Lau&author=H.H.+de+Boer&volume=1&publication_year=2022&pages=74-79&doi=10.1007/s12024-021-00440-7&)] [PMC free article](/pmc/articles/PMC8614237/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34849183)] [ [CrossRef](//doi.org/10.1016%2Fj.radcr.2021.10.053)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Radiol+Case+Reports&title=Cervical+longitudinally+extensive+myelitis+after+vaccination+with+inactivated+virus-based+COVID-19+vaccine&author=M.+Sepahvand&author=N.+Yazdi&author=M.+Rohani&author=M.+Emamikhah&volume=17&publication_year=2022&pages=303-305&doi=10.1016/j.radcr.2021.10.053&)] [PMC free article](/pmc/articles/PMC8605821/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34841097)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=eNeurologicalSci&title=An+88-year-old+woman+with+acute+disseminated+encephalomyelitis+following+messenger+ribonucleic+acid-based+COVID-19+vaccination&author=M.+Shimizu&author=K.+Ogaki&author=R.+Nakamura&author=E.+Kado&author=S.+Nakajima&volume=25&publication_year=2021&pages=100381&pmid=34841097&)] [PMC free article](/pmc/articles/PMC8499787/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34432055)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=QJM&title=Myeloperoxidase+anti-neutrophil+cytoplasmic+antibody+positive+optic+perineuritis+after+mRNA+coronavirus+disease-19+vaccine&author=T.+Takenaka&author=M.+Matsuzaki&author=S.+Fujiwara&author=M.+Hayashida&author=H.+Suyama&volume=114&publication_year=2021&pages=737-738&pmid=34432055&)] [PMC free article](/pmc/articles/PMC8656147/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34922126)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577785)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=New+diagnosis+of+multiple+sclerosis+in+the+setting+of+mRNA+COVID-19+vaccine+exposure&author=K.+Toljan&author=M.+Amin&author=A.+Kunchok&author=D.+Ontaneda&volume=362&publication_year=2022&pages=577785&pmid=34922126&doi=10.1016/j.jneuroim.2021.577785&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/34370410)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ideggyogy+Sz&title=Acute+transverse+myelitis+after+inactivated+COVID-19+vaccine&author=N.+\u015eim\u015fek+Erdem&author=S.+Demirci&author=T.+\u00d6zel&author=K.+Mamadova&author=K.+Karaali&volume=57&publication_year=2021&pages=273-276&)] [PMC free article](/pmc/articles/PMC8325554/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34392078)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577686)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=Acute+myelitis+and+ChAdOx1+nCoV-19+vaccine:+Casual+or+causal+association?&author=E.+Vegezzi&author=S.+Ravaglia&author=G.+Buongarzone&author=P.+Bini&author=L.+Diamanti&volume=359&publication_year=2021&pages=577686&pmid=34392078&doi=10.1016/j.jneuroim.2021.577686&)] [PMC free article](/pmc/articles/PMC8294707/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34325334)] [ [CrossRef](//doi.org/10.1016%2Fj.clineuro.2021.106839)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Neurol+Neurosurg&title=Acute+disseminated+encephalomyelitis+after+SARS-CoV-2+vaccination&author=A.+Vogrig&author=F.+Janes&author=G.L.+Gigli&author=F.+Curcio&author=I.+del+Negro&volume=208&publication_year=2021&pages=106839&pmid=34325334&doi=10.1016/j.clineuro.2021.106839&)] [PMC free article](/pmc/articles/PMC8516014/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34660149)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cureus&title=Neuromyelitis+Optica+in+a+Healthy+Female+After+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+mRNA-1273+Vaccine&author=P.+Fujikawa&author=F.A.+Shah&author=M.+Braford&author=K.+Patel&author=J.+Madey&volume=13&publication_year=2021&pages=e17961&pmid=34660149&)] [PMC free article](/pmc/articles/PMC8813636/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35136277)] [ [CrossRef](//doi.org/10.1016%2Fj.nrl.2022.01.003)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurolog\u00eda&title=\u201cWine+Glass\u201d+sign+following+COVID-19+vaccination+in+a+previously+healthy+adult&author=R.+Ghosh&author=S.M.G.+Dutta&publication_year=2022&doi=10.1016/j.nrl.2022.01.003&)] [PMC free article](/pmc/articles/PMC8193159/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34115170)] [ [CrossRef](//doi.org/10.1007%2Fs00415-021-10648-w)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=First+manifestation+of+multiple+sclerosis+after+immunization+with+the+Pfizer-BioNTech+COVID-19+vaccine&author=J.+Havla&author=Y.+Schultz&author=H.+Zimmermann&author=R.+Hohlfeld&author=A.+Danek&volume=269&publication_year=2022&pages=55-58&pmid=34115170&doi=10.1007/s00415-021-10648-w&)] [PMC free article](/pmc/articles/PMC8540274/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34684047)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Medicina+(Kaunas)&title=Acute+Transverse+Myelitis+after+COVID-19+Vaccination&author=Y.+Hsiao&author=M.+Tsai&author=Y.+Chen&author=C.+Hsu&volume=57&publication_year=2021&pages=10101017&)] [PMC free article](/pmc/articles/PMC8528462/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34480527)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Clin+Transl+Neurol&title=Acute+disseminated+encephalomyelitis+in+a+patient+vaccinated+against+SARS-CoV-2&author=K.+Kania&author=W.+Ambrosius&author=E.+Tokarz+Kupczyk&author=W.+Kozubski&volume=8&publication_year=2021&pages=2000-2003&pmid=34480527&)] [PMC free article](/pmc/articles/PMC8417681/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34480607)] [ [CrossRef](//doi.org/10.1007%2Fs00415-021-10780-7)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=COVID-19+mRNA+vaccination+leading+to+CNS+inflammation:+A+case+series&author=M.+Khayat-Khoei&author=S.+Bhattacharyya&author=J.+Katz&author=D.+Harrison&author=S.+Tauhid&volume=269&publication_year=2022&pages=1093-1106&pmid=34480607&doi=10.1007/s00415-021-10780-7&)] [PMC free article](/pmc/articles/PMC8083508/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33787891)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=QJM&title=COVID-19+vaccination-associated+myelitis&author=H.S.+Malhotra&author=P.+Gupta&author=V.+Prabhu&author=R.K.+Garg&author=H.+Dandu&volume=114&publication_year=2021&pages=591-593&pmid=33787891&)] [PMC free article](/pmc/articles/PMC8666465/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34903200)] [ [CrossRef](//doi.org/10.1186%2Fs12883-021-02517-w)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=A+case+report+of+ChAdOx1+nCoV-19+vaccine-associated+encephalitis&author=J.+Takata&author=S.M.+Durkin&author=S.+Wong&author=M.S.+Zandi&author=J.K.+Swanton&volume=21&publication_year=2021&pages=485&pmid=34903200&doi=10.1186/s12883-021-02517-w&)] [PMC free article](/pmc/articles/PMC8314742/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34312136)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Acute+encephalitis,+myoclonus+and+Sweet+syndrome+after+mRNA-1273+vaccine&author=G.+Torrealba-Acosta&author=J.C.+Martin&author=Y.+Huttenbach&author=C.R.+Garcia&author=M.R.+Sohail&volume=14&publication_year=2021&pages=e243173&)] [PMC free article](/pmc/articles/PMC8667462/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34927105)] [ [CrossRef](//doi.org/10.1016%2Fj.bbih.2021.100406)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Brain,+Behav+Immun-Heal&title=Aseptic+meningitis+after+BNT-162b2+COVID-19+vaccination&author=A.C.+Chan&author=B.Y.+Tan&author=Y.+Goh&author=S.S.+Tan&author=P.A.+Tambyah&volume=19&publication_year=2022&pages=100406&doi=10.1016/j.bbih.2021.100406&)] [PMC free article](/pmc/articles/PMC8354782/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34378098)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05543-1)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Aseptic+meningitis+after+vaccination+of+the+BNT162b2+mRNA+COVID-19+vaccine&author=K.+Saito&author=T.+Shimizu&author=K.+Suzuki-Inoue&author=T.+Ishida&author=Y.+Wada&volume=42&publication_year=2021&pages=4433-4435&pmid=34378098&doi=10.1007/s10072-021-05543-1&)] [PMC free article](/pmc/articles/PMC8546902/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34722067)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cureus&title=Axonal-Variant+Guillian-Barre+Syndrome+Temporally+Associated+With+mRNA-Based+Moderna+SARS-CoV-2+Vaccine&author=V.+Dalwadi&author=D.+Hancock&author=A.A.+Ballout&author=A.+Geraci&volume=13&publication_year=2021&pages=e18291&pmid=34722067&)] [PMC free article](/pmc/articles/PMC8522664/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34649856)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Guillain-Barr\u00e9+syndrome+presenting+with+facial+diplegia+following+COVID-19+vaccination+in+two+patients&author=G.+Kanabar&author=P.+Wilkinson&volume=14&publication_year=2021&pages=e244527&)] [PMC free article](/pmc/articles/PMC8327820/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34330729)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Guillain-Barr\u00e9+syndrome+after+COVID-19+vaccination&author=N.+McKean&author=C.+Chircop&volume=14&publication_year=2021&pages=e244125&)] [PMC free article](/pmc/articles/PMC8447540/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34560365)] [ [CrossRef](//doi.org/10.1016%2Fj.jneuroim.2021.577719)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=AstraZeneca+COVID-19+vaccine+and+Guillain-+Barr\u00e9+Syndrome+in+Tasmania:+A+causal+link?&author=W.M.+Oo&author=P.+Giri&author=A.+de+Souza&volume=360&publication_year=2021&pages=577719&pmid=34560365&doi=10.1016/j.jneuroim.2021.577719&)] [PMC free article](/pmc/articles/PMC8070856/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33888484)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=ChAdOx1.+BMJ+Case+Rep&title=Guillain-Barre+syndrome+following+the+first+dose+of+the+chimpanzee+adenovirus-vectored+COVID-19+vaccine&author=S.U.+Patel&author=R.+Khurram&author=A.+Lakhani&author=B.+Quirk&volume=14&publication_year=2021&pages=1-5&)] [PMC free article](/pmc/articles/PMC8462911/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34567447)] [ [CrossRef](//doi.org/10.1080%2F20009666.2021.1954284)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Community+Hosp+Intern+Med+Perspect&title=A+case+of+Guillain\u2013Barre+syndrome+following+Pfizer+COVID-19+vaccine&author=S.J.+Rao&author=S.+Khurana&author=G.+Murthy&author=E.T.+Dawson&author=N.+Jazebi&volume=11&publication_year=2021&pages=597-600&pmid=34567447&doi=10.1080/20009666.2021.1954284&)] [PMC free article](/pmc/articles/PMC8331323/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34346014)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05523-5)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Guillain-Barr\u00e9+syndrome+following+BNT162b2+COVID-19+vaccine&author=M.+Trimboli&author=P.+Zoleo&author=G.+Arabia&author=A.+Gambardella&volume=42&publication_year=2021&pages=4401-4402&pmid=34346014&doi=10.1007/s10072-021-05523-5&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/34370408)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ideggyogy+Sz&title=A+variant+of+Guillain-Barre+syndrome+after+sars-cov-2+vaccination:+Amsan&author=N.K.+Tutar&author=T.+Eyig\u00fcrb\u00fcz&author=Z.+Yildirim&author=N.+Kale&volume=74&publication_year=2021&pages=286-288&pmid=34370408&)] [PMC free article](/pmc/articles/PMC8285283/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34272622)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05467-w)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=A+case+of+acute+demyelinating+polyradiculoneuropathy+with+bilateral+facial+palsy+after+ChAdOx1+nCoV-19+vaccine&author=N.+Alessandro&author=F.+de+Marchi&author=M.+Cecchin&author=I.+de+Paoli&author=S.+Onorato&volume=19&publication_year=2021&pages=4747-4749&doi=10.1007/s10072-021-05467-w&)] [PMC free article](/pmc/articles/PMC8566211/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34763263)] [ [CrossRef](//doi.org/10.1016%2Fj.clinimag.2021.10.010)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Imaging&title=Left+Bell's+palsy+following+the+first+dose+of+mRNA-1273+SARS-CoV-2+vaccine:+A+case+report&author=M.+Cellina&author=A.+D\u2019Arrigo&author=C.+Floridi&author=G.+Oliva&author=G.+Carrafiello&volume=82&publication_year=2022&pages=1-4&pmid=34763263&doi=10.1016/j.clinimag.2021.10.010&)] [PMC free article](/pmc/articles/PMC8653229/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34725821)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=Multiple+cranial+nerve+palsies+following+COVID.+Case+report&author=M.M.+Manea&author=D.+Drago\u0219&author=I.+Enache&author=A.+George&author=S.+Tuta&volume=145&publication_year=2022&pages=257-259&pmid=34725821&)] [PMC free article](/pmc/articles/PMC8318623/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34322761)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05496-5)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Bell's+palsy+following+COVID-19+vaccination+with+high+CSF+antibody+response&author=M.+Obermann&author=M.+Krasniqi&author=N.+Ewers&author=J.+Fayad&author=U.+Haeberle&volume=42&publication_year=2021&pages=4397-4399&pmid=34322761&doi=10.1007/s10072-021-05496-5&)] [PMC free article](/pmc/articles/PMC8649466/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34816739)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Int+Med+Res&title=Leg+paralysis+after+AstraZeneca+COVID-19+vaccination+diagnosed+as+neuralgic+amyotrophy+of+the+lumbosacral+plexus:+A+case+report&author=S.Il.+Kim&author=H.Y.+Seok&author=J.+Yi&volume=49&publication_year=2021&pages=1-5&)] [PMC free article](/pmc/articles/PMC8250573/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33890680)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Muscle+Nerve&title=Parsonage+Turner+syndrome+after+COVID-19+vaccination&author=S.+Mahajan&author=F.+Zhang&author=A.+Mahajan&author=S.+Zimnowodzk&volume=64&publication_year=2021&pages=E3-E4&pmid=33890680&)] [PMC free article](/pmc/articles/PMC8667016/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34903275)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Med+Case+Rep&title=Parsonage-Turner+syndrome+following+coronavirus+disease+2019+immunization+with+ChAdOx1-S+vaccine:+A+case+report+and+review+of+the+literature&author=B.K.+Vitturi&author=M.+Grandis&author=S.+Beltramini&author=A.+Orsi&author=A.+Schenone&volume=15&publication_year=2021&pages=589&pmid=34903275&)] [PMC free article](/pmc/articles/PMC8319586/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34324120)] [ [CrossRef](//doi.org/10.1007%2Fs10072-021-05504-8)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Functional+neurological+disorder+after+COVID-19+vaccination&author=T.+Ercoli&author=L.+Lutzoni&author=G.+Orofino&author=A.+Muroni&author=G.+Defazio&volume=42&publication_year=2021&pages=3989-3990&pmid=34324120&doi=10.1007/s10072-021-05504-8&)] [PMC free article](/pmc/articles/PMC8663753/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34909338)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cureus&title=Oral+Herpes+Zoster+Infection+Following+COVID-19+Vaccination?:+A+Report+of+Five+Cases+Case+Presentation&author=H.+Fukuoka&author=N.+Fukuoka&author=T.+Kibe&author=R.S.+Tubbs&author=J.+Iwanaga&volume=13&publication_year=2021&pages=e19433&pmid=34909338&)] [PMC free article](/pmc/articles/PMC8652627/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34554601)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Anat&title=A+narrative+review+and+clinical+anatomy+of+herpes+zoster+infection+following+COVID-19+vaccination&author=J.+Iwanaga&author=H.+Fukuoka&author=N.+Fukuoka&author=H.+Yutori&author=S.+Ibaragi&volume=35&publication_year=2022&pages=45-51&pmid=34554601&)]", "language": null, "image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0", "pagetype": "article", "links": ["#main-content", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", "/pmc/", "https://www.ncbi.nlm.nih.gov/pmc/advanced", "/pmc/about/userguide/", "/pmc/journals/", "/pmc/?term=Elsevier%20PMC%20COVID-19%20Collection[filter]", "/pmc/articles/PMC9554338/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9554338%2F&text=Manifestaciones%20neurol%F3gicas%20asociadas%20a%20la%20vacuna%20contra%20COVID-19", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9554338%2F", "/pmc/journals/", "/pmc/?term=Elsevier%20PMC%20COVID-19%20Collection[filter]", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "//doi.org/10.1016%2Fj.nrl.2022.09.005", "https://pubmed.ncbi.nlm.nih.gov/36245941", "#", "#", "https://pubmed.ncbi.nlm.nih.gov/?term=Alonso%20Castillo%20R%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Mart\u00ednez%20Castrillo%20J%5BAuthor%5D", "#", "#", "#", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "#", "/pmc/articles/PMC9554338/bin/mmc1.doc", "#bib0495", "#bib0500", "#bib0495", "#bib0505", "#bib0495", "#bib0510", "#bib0515", "#bib0510", "#bib0520", "#bib0525", "#bib0530", "#bib0535", "#bib0540", "#bib0505", "#bib0545", "#bib0550", "#bib0555", "#sec0140", "/pmc/articles/PMC9554338/figure/fig0005/", "/pmc/articles/PMC9554338/figure/fig0005/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=9554338_gr1_lrg.jpg", "/pmc/articles/PMC9554338/figure/fig0005/?report=objectonly", "/pmc/articles/PMC9554338/figure/fig0005/", "/pmc/articles/PMC9554338/table/tbl0005/", "/pmc/articles/PMC9554338/table/tbl0005/?report=objectonly", "#sec0140", "#bib0515", "#bib0560", "#bib0565", "#bib0570", "#bib0520", "#bib0575", "#bib0580", "#bib0585", "#bib0590", "#bib0595", "#bib0600", "#bib0605", "#sec0140", "#sec0140", "#sec0140", "#sec0140", "#sec0140", "#sec0140", "#sec0140", "#bib0610", "#sec0140", "#sec0140", "#sec0140", "#bib0580", "#bib0615", "#bib0505", "#bib0505", "#bib0620", "#bib0495", "#bib0550", "#bib0625", "#bib0630", "#bib0495", "#bib0500", "#bib0510", "#bib0625", "#bib0500", "#bib0635", "#bib0580", "#bib0520", "#bib0575", "#bib0640", "#bib0495", "#bib0550", "#bib0590", "#bib0630", "#bib0550", "#bib0590", "#bib0630", "#bib0535", "#bib0625", "#bib0630", "#bib0645", "#bib0560", "#bib0565", "#bib0590", "#bib0630", "#bib0635", "#bib0650", "#bib0500", "#bib0655", "#bib0500", "#bib0500", "#bib0660", "#bib0635", "#bib0665", "#bib0670", "#bib0675", "#bib0680", "#bib0685", "#bib0690", "#bib0695", "#bib0700", "#bib0705", "#bib0515", "#bib0515", "#bib0570", "#bib0525", "#bib0530", "#bib0535", "#bib0540", "#bib0545", "//doi.org/10.1016/j.nrl.2022.09.005", "/pmc/articles/PMC9554338/bin/mmc1.doc", "/pmc/articles/PMC8557950/", "https://pubmed.ncbi.nlm.nih.gov/34719776", "//doi.org/10.1007%2Fs10072-021-05662-9", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Spectrum+of+neurological+complications+following+COVID-19+vaccination&author=R.K.+Garg&author=V.K.+Paliwal&volume=43&publication_year=2022&pages=3-40&pmid=34719776&doi=10.1007/s10072-021-05662-9&", "/pmc/articles/PMC8577051/", "https://pubmed.ncbi.nlm.nih.gov/34839149", "//doi.org/10.1016%2Fj.jneuroim.2021.577765", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=A+systematic+review+of+cases+of+CNS+demyelination+following+COVID-19+vaccination&author=I.I.+Ismail&author=S.+Salama&volume=362&publication_year=2022&pages=577765&pmid=34839149&doi=10.1016/j.jneuroim.2021.577765&", "/pmc/articles/PMC8366487/", "https://pubmed.ncbi.nlm.nih.gov/34398270", "//doi.org/10.1007%2Fs00415-021-10747-8", "https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=Interpretation+of+vaccine+associated+neurological+adverse+events:+A+methodological+and+historical+review&author=M.+Cauchi&author=H.+Ball&author=Y.+Ben-Shlomo&author=N.+Robertson&volume=269&publication_year=2022&pages=493-503&pmid=34398270&doi=10.1007/s00415-021-10747-8&", "/pmc/articles/PMC8250748/", "https://pubmed.ncbi.nlm.nih.gov/33779985", "https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=The+potential+neurological+effect+of+the+COVID-19+vaccines:+A+review&author=L.+Lu&author=W.+Xiong&author=J.+Mu&author=Q.+Zhang&author=H.+Zhang&volume=144&publication_year=2021&pages=3-12&pmid=33779985&", "/pmc/articles/PMC8473382/", "https://pubmed.ncbi.nlm.nih.gov/34579259", "https://scholar.google.com/scholar_lookup?journal=Vaccines&title=Reporting+of+acute+inflammatory+neuropathies+with+covid-19+vaccines:+Subgroup+disproportionality+analyses+in+vigibase&author=R.+Noseda&author=P.+Ripellino&author=S.+Ghidossi&author=R.+Bertoli&author=A.+Ceschi&volume=9&publication_year=2021&pages=1022&pmid=34579259&", "/pmc/articles/PMC8629105/", "https://pubmed.ncbi.nlm.nih.gov/34697502", "https://scholar.google.com/scholar_lookup?journal=Nat+Med&title=Neurological+complications+after+first+dose+of+COVID-19+vaccines+and+SARS-CoV-2+infection&author=M.+Patone&author=L.+Handunnetthi&author=D.+Saatci&author=J.+Pan&author=S.V.+Katikireddi&volume=27&publication_year=2021&pages=2144-2153&pmid=34697502&", "/pmc/articles/PMC7723445/", "https://pubmed.ncbi.nlm.nih.gov/33306989", "https://scholar.google.com/scholar_lookup?journal=Lancet&title=Safety+and+efficacy+of+the+ChAdOx1+nCoV-19+vaccine+(AZD1222)+against+SARS-CoV-2:+An+interim+analysis+of+four+randomised+controlled+trials+in+Brazil+South+Africa,+and+the+UK&author=M.+Voysey&author=S.+Ann&author=C.+Clemens&author=S.A.+Madhi&author=L.Y.+Weckx&volume=397&publication_year=2021&pages=99-111&pmid=33306989&", "/pmc/articles/PMC7787219/", "https://pubmed.ncbi.nlm.nih.gov/33378609", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Efficacy+and+Safety+of+the+mRNA-1273+SARS-CoV-2+Vaccine&author=L.R.+Baden&author=H.M.+El+Sahly&author=B.+Essink&author=K.+Kotloff&author=S.+Frey&volume=384&publication_year=2021&pages=403-416&pmid=33378609&", "/pmc/articles/PMC7745181/", "https://pubmed.ncbi.nlm.nih.gov/33301246", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Safety+and+Efficacy+of+the+BNT162b2+mRNA+Covid-19+Vaccine&author=F.P.+Polack&author=S.J.+Thomas&author=N.+Kitchin&author=J.+Absalon&author=A.+Gurtman&volume=383&publication_year=2020&pages=2603-2615&pmid=33301246&", "/pmc/articles/PMC7821985/", "https://pubmed.ncbi.nlm.nih.gov/33440088", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Interim+Results+of+a+Phase+1-2a+Trial+of+Ad26.COV2.S+Covid-19+Vaccine&author=J.+Sadoff&author=M.+Le+Gars&author=G.+Shukarev&author=D.+Heerwegh&author=C.+Truyers&volume=384&publication_year=2021&pages=1824-1835&pmid=33440088&", "/pmc/articles/PMC8220996/", "https://pubmed.ncbi.nlm.nih.gov/33882225", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Safety+and+Efficacy+of+Single-Dose+Ad26.COV2.S+Vaccine+against+Covid-19&author=P.A.+Goepfert&author=C.+Truyers&author=H.+Fennema&author=B.+Spiessens&author=K.+Offergeld&volume=384&publication_year=2021&pages=2187-2201&pmid=33882225&", "/pmc/articles/PMC8421080/", "https://pubmed.ncbi.nlm.nih.gov/34507266", "https://scholar.google.com/scholar_lookup?journal=Clin+Imaging.&title=Neurological+symptoms+and+neuroimaging+alterations+related+with+COVID-19+vaccine:+Cause+or+coincidence?&author=D.+Goulart+Corr\u00eaa&author=L.A.+Quevedo+Ca\u00f1ete&author=G.A.+Cruz+dos+Santos&author=R.V.+de+Oliveira&author=C.O.+Brand\u00e0o&volume=80&publication_year=2021&pages=348-352&pmid=34507266&", "/pmc/articles/PMC8005924/", "https://pubmed.ncbi.nlm.nih.gov/33782057", "https://scholar.google.com/scholar_lookup?journal=BMJ&title=The+PRISMA+2020+statement:+An+updated+guideline+for+reporting+systematic+reviews&author=M.J.+Page&author=J.E.+McKenzie&author=P.M.+Bossuyt&author=I.+Boutron&author=T.C.+Hoffmann&publication_year=2021&pages=372&", "/pmc/articles/PMC8444640/", "https://pubmed.ncbi.nlm.nih.gov/34293217", "https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Post-SARS-CoV-2-vaccination+cerebral+venous+sinus+thrombosis:+An+analysis+of+cases+notified+to+the+European+Medicines+Agency&author=K.+Krzywicka&author=M.R.+Heldner&author=M.+S\u00e1nchez+van+Kammen&author=T.+van+Haaps&author=S.+Hiltunen&volume=28&publication_year=2021&pages=3656-3662&pmid=34293217&", "/pmc/articles/PMC8652752/", "https://pubmed.ncbi.nlm.nih.gov/34536256", "https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Declining+mortality+of+cerebral+venous+sinus+thrombosis+with+thrombocytopenia+after+SARS-2+vaccination&author=A.+Munckhof&author=+Van+De&author=K.+Krzywicka&author=D.+Aguiar&author=M.+S\u00e1nchez&volume=29&publication_year=2022&pages=339-344&pmid=34536256&", "/pmc/articles/PMC8418051/", "https://pubmed.ncbi.nlm.nih.gov/34492394", "//doi.org/10.1016%2Fj.ijid.2021.08.071", "https://scholar.google.com/scholar_lookup?journal=Int+J+Infect+Dis&title=Facial+nerve+palsy+following+the+administration+of+COVID-19+mRNA+vaccines:+Analysis+of+a+self-reporting+database&author=K.+Sato&author=T.+Mano&author=Y.+Niimi&author=T.+Toda&author=A.+Iwata&volume=111&publication_year=2021&pages=310-312&pmid=34492394&doi=10.1016/j.ijid.2021.08.071&", "/pmc/articles/PMC8213977/", "https://pubmed.ncbi.nlm.nih.gov/34147649", "https://scholar.google.com/scholar_lookup?journal=Clin+Immunol&title=Neurologic+adverse+events+among+704,003+first-dose+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine+in+Mexico:+A+nationwide+descriptive+study&author=M.+Garc\u00eda-Grimshaw&author=S.E.+Ceballos-Liceaga&author=L.E.+Hern\u00e1ndez-Vanegas&author=I.+N\u00fa\u00f1ez&author=N.+Hern\u00e1ndez-Valdivia&volume=229&publication_year=2021&pages=108786&pmid=34147649&", "/pmc/articles/PMC8554108/", "https://pubmed.ncbi.nlm.nih.gov/34742595", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Transient+sensory+symptoms+among+first-dose+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine:+A+case-control+study&author=M.+Garc\u00eda-Grimshaw&author=S.E.+Ceballos-Liceaga&author=A.+Michel-Ch\u00e1vez&author=M.+Garc\u00eda-Alanis&author=A.+Cadena-Fern\u00e1ndez&volume=39&publication_year=2021&pages=6975-6979&pmid=34742595&", "/pmc/articles/PMC8332675/", "https://pubmed.ncbi.nlm.nih.gov/34358692", "https://scholar.google.com/scholar_lookup?journal=Clin+Immunol&title=Guillain-Barr\u00e9+syndrome+is+infrequent+among+recipients+of+the+BNT162b2+mRNA+COVID-19+vaccine&author=M.+Garc\u00eda-Grimshaw&author=A.+Michel-Ch\u00e1vez&author=J.M.+Vera-Zertuche&author=J.A.+Galnares-Olalde&author=L.E.+Hern\u00e1ndez-Vanegas&volume=230&publication_year=2021&pages=108818&pmid=34358692&", "/pmc/articles/PMC8186447/", "https://pubmed.ncbi.nlm.nih.gov/34116145", "https://scholar.google.com/scholar_lookup?journal=J+Am+Coll+Cardiol&title=Cerebral+Venous+Sinus+Thrombosis+in+the+U.S.+Population+After+Adenovirus-Based+SARS-CoV-2+Vaccination,+and+After+COVID-19&author=B.+Bikdeli&author=S.+Chatterjee&author=S.+Arora&author=M.+Monreal&author=D.+Jimenez&volume=78&publication_year=2021&pages=408-411&pmid=34116145&", "/pmc/articles/PMC8511874/", "https://pubmed.ncbi.nlm.nih.gov/34688190", "//doi.org/10.1016%2Fj.jns.2021.120030", "https://scholar.google.com/scholar_lookup?journal=J+Neurol+Sci&title=Hospital-based+observational+study+of+neurological+disorders+in+patients+recently+vaccinated+with+COVID-19+mRNA+vaccines&author=J.S.+Koh&author=R.H.M.+Hoe&author=M.H.+Yong&author=H.J.+Chiew&author=Y.+Goh&volume=430&publication_year=2021&pages=120030&pmid=34688190&doi=10.1016/j.jns.2021.120030&", "/pmc/articles/PMC8346241/", "https://pubmed.ncbi.nlm.nih.gov/34370972", "https://scholar.google.com/scholar_lookup?journal=Lancet&title=Cerebral+venous+thrombosis+after+vaccination+against+COVID-19+in+the+UK:+Multicentre+cohort+study&author=R.J.+Perry&author=A.+Tamborska&author=B.+Singh&author=B.+Craven&author=R.+Marigold&volume=398&publication_year=2021&pages=1147-1156&pmid=34370972&", "/pmc/articles/PMC8427115/", "https://pubmed.ncbi.nlm.nih.gov/34288044", "https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=COVID-19+Vaccine-Associated+Cerebral+Venous+Thrombosis+in+Germany&author=J.B.+Schulz&author=P.+Berlit&author=H.+Diener&author=C.+Gerloff&author=A.+Greinacher&volume=90&publication_year=2021&pages=627-639&pmid=34288044&", "https://pubmed.ncbi.nlm.nih.gov/34467793", "https://scholar.google.com/scholar_lookup?journal=Nose+Throat+J&title=COVID-19:+Post-vaccine+Smell+Taste+Disorders:+Report+of+6+Cases+Ear&author=J.R.+Lechien&author=A.O.+Diallo&author=B.+Dachy&author=S.D.+Le+Bon&author=A.+Maniaci&publication_year=2021&", "/pmc/articles/PMC8105133/", "https://pubmed.ncbi.nlm.nih.gov/34000712", "https://scholar.google.com/scholar_lookup?journal=Diabetes+Metab+Syndr+Clin+Res+Rev&title=Focal+onset+non-motor+seizure+following+COVID-19+vaccination:+A+mere+coincidence?&author=R.+Ghosh&author=S.+Dubey&author=D.+Roy&author=A.+Mandal&author=D.+Naga&volume=15&publication_year=2021&pages=1023-1024&", "/pmc/articles/PMC8548963/", "https://pubmed.ncbi.nlm.nih.gov/34475124", "https://scholar.google.com/scholar_lookup?journal=Neurology&title=Neurologic+Safety+Monitoring+of+COVID-19+Vaccines:+Lessons+from+the+Past+to+Inform+the+Present&author=K.T.+Thakur&author=S.+Epstein&author=A.+Bilski&author=A.+Balbi&author=A.K.+Boehme&volume=97&publication_year=2021&pages=767-775&pmid=34475124&", "/pmc/articles/PMC8330139/", "https://pubmed.ncbi.nlm.nih.gov/34365148", "//doi.org/10.1016%2Fj.jns.2021.117607", "https://scholar.google.com/scholar_lookup?journal=J+Neurol+Sci&title=Vaccine-induced+immune+thrombotic+thrombocytopenia+and+cerebral+venous+sinus+thrombosis+post+COVID-19+vaccination;+A+systematic+review&author=M.+Sharifian-Dorche&author=M.+Bahmanyar&author=A.+Sharifian-Dorche&author=P.+Mohammadi&author=M.+Nomovi&volume=428&publication_year=2021&pages=117607&pmid=34365148&doi=10.1016/j.jns.2021.117607&", "/pmc/articles/PMC8056834/", "https://pubmed.ncbi.nlm.nih.gov/33857630", "//doi.org/10.1016%2Fj.bbi.2021.04.006", "https://scholar.google.com/scholar_lookup?journal=Brain+Behav+Immun&title=Cerebral+venous+sinus+thrombosis+and+thrombocytopenia+after+COVID-19+vaccination+-+A+report+of+two+UK+cases&author=P.R.+Mehta&author=S.+Apap+Mangion&author=M.+Benger&author=B.R.+Stanton&author=J.+Czuprynska&volume=95&publication_year=2021&pages=514-517&pmid=33857630&doi=10.1016/j.bbi.2021.04.006&", "/pmc/articles/PMC8652629/", "https://pubmed.ncbi.nlm.nih.gov/34668274", "https://scholar.google.com/scholar_lookup?journal=Eur+J+Neurol&title=Neurological+autoimmune+diseases+following+vaccinations+against+SARS-CoV-2:+A+case+series&author=L.D.+Kaulen&author=S.+Doubrovinskaia&author=C.+Mooshage&author=B.+Jordan&author=J.+Purrucker&volume=29&publication_year=2022&pages=555-563&pmid=34668274&", "/pmc/articles/PMC9082459/", "https://pubmed.ncbi.nlm.nih.gov/35233819", "https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Neurological+Events+Reported+after+COVID-19+Vaccines:+An+Analysis+of+Vaccine+Adverse+Event+Reporting+System&author=J.A.+Frontera&author=A.A.+Tamborska&author=M.F.+Doheim&author=D.+Garcia-azorin&author=H.+Gezegen&volume=91&publication_year=2022&pages=756-771&", "/pmc/articles/PMC8344576/", "https://pubmed.ncbi.nlm.nih.gov/34247246", "https://scholar.google.com/scholar_lookup?journal=QJM&title=COVID-19+vaccine-associated+acute+cerebral+venous+thrombosis+pulmonary+artery+embolism&author=R.+Wang&author=W.+Chiang&author=H.+Shyu&author=M.+Chen&author=C.+Lin&volume=114&publication_year=2021&pages=506-507&pmid=34247246&", "/pmc/articles/PMC8426979/", "https://pubmed.ncbi.nlm.nih.gov/34324214", "https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Postvaccinal+Encephalitis+after+ChAdOx1+nCov-19&author=F.+Zuhorn&author=T.+Graf&author=R.+Klingebiel&author=W.R.+Sch\u00e4bitz&author=A.+Rogalewski&volume=90&publication_year=2021&pages=506-511&pmid=34324214&", "/pmc/articles/PMC8653244/", "https://pubmed.ncbi.nlm.nih.gov/34900001", "https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Neuroimmunol&title=Optic+neuritis+after+COVID-19+vaccine+application&author=C.+Garc\u00eda-Estrada&author=E.+G\u00f3mez-Figueroa&author=L.+Alban&author=A.+Arias-C\u00e1rdenas&volume=00&publication_year=2021&pages=1-3&", "/pmc/articles/PMC8506086/", "https://pubmed.ncbi.nlm.nih.gov/34641797", "//doi.org/10.1186%2Fs12883-021-02427-x", "https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=Longitudinal+extensive+transverse+myelitis+following+ChAdOx1+nCOV-19+vaccine:+A+case+report&author=W.Y.+Tan&author=A.H.K.+Yusof+Khan&author=M.N.+Mohd+Yaakob&author=A.M.+Abdul+Rashid&author=W.C.+Loh&volume=21&publication_year=2021&pages=395&pmid=34641797&doi=10.1186/s12883-021-02427-x&", "/pmc/articles/PMC8241205/", "https://pubmed.ncbi.nlm.nih.gov/34189662", "//doi.org/10.1007%2Fs10072-021-05427-4", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Watch+out+for+neuromyelitis+optica+spectrum+disorder+after+inactivated+virus+vaccination+for+COVID-19&author=S.+Chen&author=X.+Rui&author=F.+Shuang&author=H.+Jie&author=W.+Zhang&volume=42&publication_year=2021&pages=3537-3539&pmid=34189662&doi=10.1007/s10072-021-05427-4&", "/pmc/articles/PMC8653182/", "https://pubmed.ncbi.nlm.nih.gov/34900000", "https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Neuroimmunol&title=Guillain\u2013Barr\u00e9+syndrome+after+coronavirus+disease+2019+vaccine:+A+temporal+association&author=G.F.+da+Silva&author=C.F.+da+Silva&author=R.E.N.+da+Oliveira&author=F.+Romancini&author=R.M.+Mendes&volume=00&publication_year=2021&pages=1-3&", "/pmc/articles/PMC8405530/", "https://pubmed.ncbi.nlm.nih.gov/34484780", "https://scholar.google.com/scholar_lookup?journal=Clin+Case+Reports&title=COVID-19+vaccine+causing+Guillain-Barre+syndrome,+a+rare+potential+side+effect&author=A.S.+Matarneh&author=A.H.+Al-battah&author=K.+Farooqui&author=M.+Ghamoodi&author=M.+Alhatou&volume=9&publication_year=2021&pages=e04756&", "/pmc/articles/PMC8598937/", "https://pubmed.ncbi.nlm.nih.gov/34789193", "//doi.org/10.1186%2Fs12883-021-02489-x", "https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=Miller+Fisher+syndrome+following+BNT162b2+mRNA+coronavirus+2019+vaccination&author=Y.+Nishiguchi&author=H.+Matsuyama&author=K.+Maeda&author=A.+Shindo&author=H.+Tomimoto&volume=21&publication_year=2021&pages=452&pmid=34789193&doi=10.1186/s12883-021-02489-x&", "/pmc/articles/PMC8346349/", "https://pubmed.ncbi.nlm.nih.gov/34538679", "//doi.org/10.1016%2Fj.jemermed.2021.07.062", "https://scholar.google.com/scholar_lookup?journal=J+Emerg+Med&title=Guillain-Barr\u00e9+Syndrome+Presenting+as+Facial+Diplegia+after+COVID-19+Vaccination:+A+Case+Report&author=A.+Rossetti&author=G.+Gheihman&author=M.+O\u2019Hare&author=J.M.+Kosowsky&volume=61&publication_year=2021&pages=e141-e145&pmid=34538679&doi=10.1016/j.jemermed.2021.07.062&", "https://pubmed.ncbi.nlm.nih.gov/34779385", "//doi.org/10.1016%2Fj.jemermed.2021.07.062", "https://scholar.google.com/scholar_lookup?journal=Acta+Medica+(Hradec+Kralove)&title=Guillan-Barr\u00e9+Syndrome+after+First+Vaccination+Dose+against+COVID-19:+Case+Report&author=D.+\u010cen\u0161\u010d\u00e1k&author=L.+Ungermann&author=I.+\u0160t\u011btk\u00e1\u0159ov\u00e1&author=E.+Ehler&volume=64&publication_year=2021&pages=183-186&pmid=34779385&doi=10.1016/j.jemermed.2021.07.062&", "/pmc/articles/PMC8634230/", "https://pubmed.ncbi.nlm.nih.gov/34848426", "https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Miller-Fisher+Syndrome+and+Guillain-Barre+Syndrome+overlap+syndrome+in+a+patient+post+Oxford-AstraZeneca+SARS-CoV-2+vaccination&author=Y.L.+Dang&author=A.+Bryson&volume=14&publication_year=2021&pages=e246701&", "/pmc/articles/PMC8652921/", "https://pubmed.ncbi.nlm.nih.gov/34528279", "https://scholar.google.com/scholar_lookup?journal=Ann+Neurol&title=Guillain-Barr\u00e9+Syndrome+in+an+Australian+State+Using+Both+mRNA+and+Adenovirus-Vector+SARS-CoV-2+Vaccines&author=J.+Osowicki&author=H.+Morgan&author=A.+Harris&author=N.W.+Crawford&author=J.P.+Buttery&volume=90&publication_year=2021&pages=856-858&pmid=34528279&", "/pmc/articles/PMC8349403/", "https://pubmed.ncbi.nlm.nih.gov/34416410", "//doi.org/10.1016%2Fj.jneuroim.2021.577691", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=Sensory+Guillain-Barre+syndrome+following+the+ChAdOx1+nCov-19+vaccine:+Report+of+two+cases+and+review+of+literature&author=Y.G.+Min&author=W.+Ju&author=Y.E.+Ha&author=J.J.+Ban&author=S.A.+Lee&volume=359&publication_year=2021&pages=577691&pmid=34416410&doi=10.1016/j.jneuroim.2021.577691&", "/pmc/articles/PMC8420211/", "https://pubmed.ncbi.nlm.nih.gov/34133027", "https://scholar.google.com/scholar_lookup?journal=Am+Event+J+Hematol&title=Cerebral+venous+thrombosis+post+BNT162b2+SARS-CoV-2+vaccination:+mRNA.+black+swan+A&author=B.E.+Fan&author=J.Y.+Shen&author=X.R.+Lim&author=T.M.+Tu&author=C.C.R.+Chang&volume=96&publication_year=2021&pages=E357-E361&", "/pmc/articles/PMC8140563/", "https://pubmed.ncbi.nlm.nih.gov/34023956", "//doi.org/10.1007%2Fs00415-021-10599-2", "https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=Immediate+high-dose+intravenous+immunoglobulins+followed+by+direct+thrombin-inhibitor+treatment+is+crucial+for+survival+in+Sars-Covid-19-adenoviral+vector+vaccine-induced+immune+thrombotic+thrombocytopenia+VITT+with+cerebral+sinus+venous+and+portal+vein+t&author=T.+Graf&author=T.+Thiele&author=R.+Klingebiel&author=A.+Greinacher&author=W.+R\u00fcdiger&volume=268&publication_year=2021&pages=4483-4485&pmid=34023956&doi=10.1007/s00415-021-10599-2&", "/pmc/articles/PMC8717801/", "https://pubmed.ncbi.nlm.nih.gov/34244448", "https://scholar.google.com/scholar_lookup?journal=Stroke+Vasc+Neurol&title=Cerebral+venous+sinus+thrombosis+after+19+vaccination+with+a+misleading+first+cerebral+MRI+scan&author=B.+Ikenberg&author=A.F.+Demleitner&author=T.+Thiele&author=B.+Wiestler&author=K.+G\u00f6tze&volume=6&publication_year=2021&pages=e001095&", "/pmc/articles/PMC8397593/", "https://pubmed.ncbi.nlm.nih.gov/34461442", "https://scholar.google.com/scholar_lookup?journal=J+Stroke+Cerebrovasc+Dis&title=Treatment+of+ChAdOx1+nCoV-19+Vaccine-Induced+Immune+Thrombotic+Thrombocytopenia+Related+Acute+Ischemic+Stroke&author=J.+Kenda&author=D.+Lovri\u010d&author=M.+\u0160kerget&author=N.+Milivojevi\u0107&volume=30&publication_year=2021&pages=106072&pmid=34461442&", "/pmc/articles/PMC8422498/", "https://pubmed.ncbi.nlm.nih.gov/34513173", "https://scholar.google.com/scholar_lookup?journal=Surg+Neurol+Int&title=A+rare+case+of+vaccine-induced+immune+thrombosis+and+thrombocytopenia+and+approach+to+management&author=R.+Kotal&author=I.+Jacob&author=P.+Rangappa&author=K.+Rao&author=G.+Hosurkar&volume=12&publication_year=2021&pages=408&pmid=34513173&", "/pmc/articles/PMC8552183/", "https://pubmed.ncbi.nlm.nih.gov/34706921", "https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Cerebral+venous+sinus+thrombosis+after+ChAdOx1+vaccination:+The+first+case+of+definite+thrombosis+with+thrombocytopenia+syndrome+from+India&author=B.V.+Maramattom&author=F.M.+Moidu&author=S.+Varikkottil&author=A.A.+Syed&volume=14&publication_year=2021&pages=e246455&", "/pmc/articles/PMC8112568/", "https://pubmed.ncbi.nlm.nih.gov/33835768", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med.&title=Thrombosis+and+Thrombocytopenia+after+ChAdOx1+nCoV-19+Vaccination&author=N.H.+Schultz&author=I.H.+S\u00f8rvoll&author=A.E.+Michelsen&author=L.A.+Munthe&author=F.+Lund-Johansen&volume=384&publication_year=2021&pages=2124-2130&pmid=33835768&", "/pmc/articles/PMC8219289/", "https://pubmed.ncbi.nlm.nih.gov/34137813", "https://scholar.google.com/scholar_lookup?journal=Blood+Adv&title=A+case+of+thrombocytopenia+and+multiple+thromboses+after+vaccination+with+ChAdOx1+nCoV-19+against+SARS-CoV-2&author=A.L.T.+Sorensen&author=M.+Rolland&author=J.+Hartmann&author=Z.B.+Harboe&author=C.+Roed&volume=5&publication_year=2021&pages=2569-2574&pmid=34137813&", "/pmc/articles/PMC8084604/", "https://pubmed.ncbi.nlm.nih.gov/34323939", "https://scholar.google.com/scholar_lookup?journal=Blood&title=Prothrombotic+immune+thrombocytopenia+after+COVID-19+vaccination&author=A.+Tiede&author=U.J.+Sachs&author=A.+Czwalinna&author=S.+Werwitzke&author=R.+Bikker&volume=138&publication_year=2021&pages=350-353&pmid=34323939&", "/pmc/articles/PMC8593397/", "https://pubmed.ncbi.nlm.nih.gov/34783932", "//doi.org/10.1007%2Fs10072-021-05714-0", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Cerebral+venous+sinus+thrombosis+after+mRNA-based+COVID-19+vaccination&author=Y.+Yagi&author=Y.+Asami&author=M.+Kyoya&author=T.+Yokota&volume=43&publication_year=2022&pages=41-43&pmid=34783932&doi=10.1007/s10072-021-05714-0&", "/pmc/articles/PMC8046413/", "https://pubmed.ncbi.nlm.nih.gov/33864750", "//doi.org/10.1016%2FS0140-6736(21)00872-2", "https://scholar.google.com/scholar_lookup?journal=Lancet&title=Bilateral+superior+ophthalmic+vein+thrombosis,+ischaemic+stroke,+and+immune+thrombocytopenia+after+ChAdOx1+nCoV-19+vaccination&author=A.+Bayas&author=M.+Menacher&author=M.+Christ&author=L.+Behrens&author=A.+Rank&volume=397&publication_year=2021&pages=e11&pmid=33864750&doi=10.1016/S0140-6736(21)00872-2&", "/pmc/articles/PMC8250306/", "https://pubmed.ncbi.nlm.nih.gov/33877737", "https://scholar.google.com/scholar_lookup?journal=J+Thromb+Haemost&title=Thrombocytopenia+with+acute+ischemic+stroke+and+bleeding+in+a+patient+newly+vaccinated+with+an+adenoviral+vector-based+COVID-+19+vaccine&author=R.A.+Blauenfeldt&author=S.R.+Kristensen&author=S.L.+Ernstsen&author=C.+Christina&author=H.+Kristensen&volume=19&publication_year=2021&pages=1771-1775&pmid=33877737&", "/pmc/articles/PMC8444739/", "https://pubmed.ncbi.nlm.nih.gov/34273119", "https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=Large+hemorrhagic+stroke+after+ChAdOx1+nCoV-19+vaccination:+A+case+report&author=M.L.+M\u00e9lo&author=S.+De&author=D.P.+Lopes&volume=144&publication_year=2021&pages=717-718&pmid=34273119&", "/pmc/articles/PMC8382847/", "https://pubmed.ncbi.nlm.nih.gov/34447349", "https://scholar.google.com/scholar_lookup?journal=Front+Neurol&title=Severe+Multiple+Sclerosis+Relapse+After+COVID-19+Vaccination:+A+Case+Report&author=G.T.+Maniscalco&author=V.+Manzo&author=M.E.+di+Battista&author=S.+Salvatore&author=O.+Moreggia&volume=12&publication_year=2021&pages=72-718&", "/pmc/articles/PMC8567291/", "https://pubmed.ncbi.nlm.nih.gov/34714721", "//doi.org/10.1080%2F21645515.2021.1971920", "https://scholar.google.com/scholar_lookup?journal=Hum+Vaccines+Immunother&title=demyelination+in+a+subject+with+cerebellar+ataxia+following+the+first+dose+of+COVID-19+vaccine;+a+case+report&author=O.+Mirmosayyeb&author=S.+Bagherieh&author=V.+Shaygannejad&author=C.N.S.+Acute&volume=17&publication_year=2021&pages=4099-4101&doi=10.1080/21645515.2021.1971920&", "/pmc/articles/PMC8943383/", "https://pubmed.ncbi.nlm.nih.gov/34897155", "https://scholar.google.com/scholar_lookup?journal=Intern+Med&title=A+Case+of+Refractory+Longitudinally+Extensive+Transverse+Myelitis+after+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+Vaccination+in+a+Japanese+Man&author=N.+Miyaue&author=A.+Yoshida&author=Y.+Yamanishi&author=S.+Tada&author=R.+Ando&volume=61&publication_year=2022&pages=739-742&pmid=34897155&", "/pmc/articles/PMC8136261/", "https://pubmed.ncbi.nlm.nih.gov/34018145", "//doi.org/10.1007%2Fs13760-021-01699-x", "https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Belg&title=Acute+disseminated+encephalomyelitis+-+like+presentation+after+an+inactivated+coronavirus+vaccine&author=G.+Ozgen&author=K.+Buse&author=C.+Ari&author=C.+Guler&author=M.+Kemal&volume=121&publication_year=2021&pages=1089-1091&pmid=34018145&doi=10.1007/s13760-021-01699-x&", "/pmc/articles/PMC8223023/", "https://pubmed.ncbi.nlm.nih.gov/34182207", "//doi.org/10.1016%2Fj.jneuroim.2021.577606", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=A+case+of+longitudinally+extensive+transverse+myelitis+following+vaccination+against+Covid-19&author=C.+Pagenkopf&author=M.+S\u00fcdmeyer&volume=358&publication_year=2021&pages=577606&pmid=34182207&doi=10.1016/j.jneuroim.2021.577606&", "/pmc/articles/PMC8567127/", "https://pubmed.ncbi.nlm.nih.gov/34735684", "//doi.org/10.1007%2Fs12024-021-00440-7", "https://scholar.google.com/scholar_lookup?journal=Forensic+Sci+Med+Pathol&title=Acute+disseminated+encephalomyelitis+(ADEM)+following+recent+Oxford/AstraZeneca+COVID-19+vaccination&author=F.+Permezel&author=B.+Borojevic&author=S.+Lau&author=H.H.+de+Boer&volume=1&publication_year=2022&pages=74-79&doi=10.1007/s12024-021-00440-7&", "/pmc/articles/PMC8614237/", "https://pubmed.ncbi.nlm.nih.gov/34849183", "//doi.org/10.1016%2Fj.radcr.2021.10.053", "https://scholar.google.com/scholar_lookup?journal=Radiol+Case+Reports&title=Cervical+longitudinally+extensive+myelitis+after+vaccination+with+inactivated+virus-based+COVID-19+vaccine&author=M.+Sepahvand&author=N.+Yazdi&author=M.+Rohani&author=M.+Emamikhah&volume=17&publication_year=2022&pages=303-305&doi=10.1016/j.radcr.2021.10.053&", "/pmc/articles/PMC8605821/", "https://pubmed.ncbi.nlm.nih.gov/34841097", "https://scholar.google.com/scholar_lookup?journal=eNeurologicalSci&title=An+88-year-old+woman+with+acute+disseminated+encephalomyelitis+following+messenger+ribonucleic+acid-based+COVID-19+vaccination&author=M.+Shimizu&author=K.+Ogaki&author=R.+Nakamura&author=E.+Kado&author=S.+Nakajima&volume=25&publication_year=2021&pages=100381&pmid=34841097&", "/pmc/articles/PMC8499787/", "https://pubmed.ncbi.nlm.nih.gov/34432055", "https://scholar.google.com/scholar_lookup?journal=QJM&title=Myeloperoxidase+anti-neutrophil+cytoplasmic+antibody+positive+optic+perineuritis+after+mRNA+coronavirus+disease-19+vaccine&author=T.+Takenaka&author=M.+Matsuzaki&author=S.+Fujiwara&author=M.+Hayashida&author=H.+Suyama&volume=114&publication_year=2021&pages=737-738&pmid=34432055&", "/pmc/articles/PMC8656147/", "https://pubmed.ncbi.nlm.nih.gov/34922126", "//doi.org/10.1016%2Fj.jneuroim.2021.577785", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=New+diagnosis+of+multiple+sclerosis+in+the+setting+of+mRNA+COVID-19+vaccine+exposure&author=K.+Toljan&author=M.+Amin&author=A.+Kunchok&author=D.+Ontaneda&volume=362&publication_year=2022&pages=577785&pmid=34922126&doi=10.1016/j.jneuroim.2021.577785&", "https://pubmed.ncbi.nlm.nih.gov/34370410", "https://scholar.google.com/scholar_lookup?journal=Ideggyogy+Sz&title=Acute+transverse+myelitis+after+inactivated+COVID-19+vaccine&author=N.+\u015eim\u015fek+Erdem&author=S.+Demirci&author=T.+\u00d6zel&author=K.+Mamadova&author=K.+Karaali&volume=57&publication_year=2021&pages=273-276&", "/pmc/articles/PMC8325554/", "https://pubmed.ncbi.nlm.nih.gov/34392078", "//doi.org/10.1016%2Fj.jneuroim.2021.577686", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=Acute+myelitis+and+ChAdOx1+nCoV-19+vaccine:+Casual+or+causal+association?&author=E.+Vegezzi&author=S.+Ravaglia&author=G.+Buongarzone&author=P.+Bini&author=L.+Diamanti&volume=359&publication_year=2021&pages=577686&pmid=34392078&doi=10.1016/j.jneuroim.2021.577686&", "/pmc/articles/PMC8294707/", "https://pubmed.ncbi.nlm.nih.gov/34325334", "//doi.org/10.1016%2Fj.clineuro.2021.106839", "https://scholar.google.com/scholar_lookup?journal=Clin+Neurol+Neurosurg&title=Acute+disseminated+encephalomyelitis+after+SARS-CoV-2+vaccination&author=A.+Vogrig&author=F.+Janes&author=G.L.+Gigli&author=F.+Curcio&author=I.+del+Negro&volume=208&publication_year=2021&pages=106839&pmid=34325334&doi=10.1016/j.clineuro.2021.106839&", "/pmc/articles/PMC8516014/", "https://pubmed.ncbi.nlm.nih.gov/34660149", "https://scholar.google.com/scholar_lookup?journal=Cureus&title=Neuromyelitis+Optica+in+a+Healthy+Female+After+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+mRNA-1273+Vaccine&author=P.+Fujikawa&author=F.A.+Shah&author=M.+Braford&author=K.+Patel&author=J.+Madey&volume=13&publication_year=2021&pages=e17961&pmid=34660149&", "/pmc/articles/PMC8813636/", "https://pubmed.ncbi.nlm.nih.gov/35136277", "//doi.org/10.1016%2Fj.nrl.2022.01.003", "https://scholar.google.com/scholar_lookup?journal=Neurolog\u00eda&title=\u201cWine+Glass\u201d+sign+following+COVID-19+vaccination+in+a+previously+healthy+adult&author=R.+Ghosh&author=S.M.G.+Dutta&publication_year=2022&doi=10.1016/j.nrl.2022.01.003&", "/pmc/articles/PMC8193159/", "https://pubmed.ncbi.nlm.nih.gov/34115170", "//doi.org/10.1007%2Fs00415-021-10648-w", "https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=First+manifestation+of+multiple+sclerosis+after+immunization+with+the+Pfizer-BioNTech+COVID-19+vaccine&author=J.+Havla&author=Y.+Schultz&author=H.+Zimmermann&author=R.+Hohlfeld&author=A.+Danek&volume=269&publication_year=2022&pages=55-58&pmid=34115170&doi=10.1007/s00415-021-10648-w&", "/pmc/articles/PMC8540274/", "https://pubmed.ncbi.nlm.nih.gov/34684047", "https://scholar.google.com/scholar_lookup?journal=Medicina+(Kaunas)&title=Acute+Transverse+Myelitis+after+COVID-19+Vaccination&author=Y.+Hsiao&author=M.+Tsai&author=Y.+Chen&author=C.+Hsu&volume=57&publication_year=2021&pages=10101017&", "/pmc/articles/PMC8528462/", "https://pubmed.ncbi.nlm.nih.gov/34480527", "https://scholar.google.com/scholar_lookup?journal=Ann+Clin+Transl+Neurol&title=Acute+disseminated+encephalomyelitis+in+a+patient+vaccinated+against+SARS-CoV-2&author=K.+Kania&author=W.+Ambrosius&author=E.+Tokarz+Kupczyk&author=W.+Kozubski&volume=8&publication_year=2021&pages=2000-2003&pmid=34480527&", "/pmc/articles/PMC8417681/", "https://pubmed.ncbi.nlm.nih.gov/34480607", "//doi.org/10.1007%2Fs00415-021-10780-7", "https://scholar.google.com/scholar_lookup?journal=J+Neurol&title=COVID-19+mRNA+vaccination+leading+to+CNS+inflammation:+A+case+series&author=M.+Khayat-Khoei&author=S.+Bhattacharyya&author=J.+Katz&author=D.+Harrison&author=S.+Tauhid&volume=269&publication_year=2022&pages=1093-1106&pmid=34480607&doi=10.1007/s00415-021-10780-7&", "/pmc/articles/PMC8083508/", "https://pubmed.ncbi.nlm.nih.gov/33787891", "https://scholar.google.com/scholar_lookup?journal=QJM&title=COVID-19+vaccination-associated+myelitis&author=H.S.+Malhotra&author=P.+Gupta&author=V.+Prabhu&author=R.K.+Garg&author=H.+Dandu&volume=114&publication_year=2021&pages=591-593&pmid=33787891&", "/pmc/articles/PMC8666465/", "https://pubmed.ncbi.nlm.nih.gov/34903200", "//doi.org/10.1186%2Fs12883-021-02517-w", "https://scholar.google.com/scholar_lookup?journal=BMC+Neurol&title=A+case+report+of+ChAdOx1+nCoV-19+vaccine-associated+encephalitis&author=J.+Takata&author=S.M.+Durkin&author=S.+Wong&author=M.S.+Zandi&author=J.K.+Swanton&volume=21&publication_year=2021&pages=485&pmid=34903200&doi=10.1186/s12883-021-02517-w&", "/pmc/articles/PMC8314742/", "https://pubmed.ncbi.nlm.nih.gov/34312136", "https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Acute+encephalitis,+myoclonus+and+Sweet+syndrome+after+mRNA-1273+vaccine&author=G.+Torrealba-Acosta&author=J.C.+Martin&author=Y.+Huttenbach&author=C.R.+Garcia&author=M.R.+Sohail&volume=14&publication_year=2021&pages=e243173&", "/pmc/articles/PMC8667462/", "https://pubmed.ncbi.nlm.nih.gov/34927105", "//doi.org/10.1016%2Fj.bbih.2021.100406", "https://scholar.google.com/scholar_lookup?journal=Brain,+Behav+Immun-Heal&title=Aseptic+meningitis+after+BNT-162b2+COVID-19+vaccination&author=A.C.+Chan&author=B.Y.+Tan&author=Y.+Goh&author=S.S.+Tan&author=P.A.+Tambyah&volume=19&publication_year=2022&pages=100406&doi=10.1016/j.bbih.2021.100406&", "/pmc/articles/PMC8354782/", "https://pubmed.ncbi.nlm.nih.gov/34378098", "//doi.org/10.1007%2Fs10072-021-05543-1", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Aseptic+meningitis+after+vaccination+of+the+BNT162b2+mRNA+COVID-19+vaccine&author=K.+Saito&author=T.+Shimizu&author=K.+Suzuki-Inoue&author=T.+Ishida&author=Y.+Wada&volume=42&publication_year=2021&pages=4433-4435&pmid=34378098&doi=10.1007/s10072-021-05543-1&", "/pmc/articles/PMC8546902/", "https://pubmed.ncbi.nlm.nih.gov/34722067", "https://scholar.google.com/scholar_lookup?journal=Cureus&title=Axonal-Variant+Guillian-Barre+Syndrome+Temporally+Associated+With+mRNA-Based+Moderna+SARS-CoV-2+Vaccine&author=V.+Dalwadi&author=D.+Hancock&author=A.A.+Ballout&author=A.+Geraci&volume=13&publication_year=2021&pages=e18291&pmid=34722067&", "/pmc/articles/PMC8522664/", "https://pubmed.ncbi.nlm.nih.gov/34649856", "https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Guillain-Barr\u00e9+syndrome+presenting+with+facial+diplegia+following+COVID-19+vaccination+in+two+patients&author=G.+Kanabar&author=P.+Wilkinson&volume=14&publication_year=2021&pages=e244527&", "/pmc/articles/PMC8327820/", "https://pubmed.ncbi.nlm.nih.gov/34330729", "https://scholar.google.com/scholar_lookup?journal=BMJ+Case+Rep&title=Guillain-Barr\u00e9+syndrome+after+COVID-19+vaccination&author=N.+McKean&author=C.+Chircop&volume=14&publication_year=2021&pages=e244125&", "/pmc/articles/PMC8447540/", "https://pubmed.ncbi.nlm.nih.gov/34560365", "//doi.org/10.1016%2Fj.jneuroim.2021.577719", "https://scholar.google.com/scholar_lookup?journal=J+Neuroimmunol&title=AstraZeneca+COVID-19+vaccine+and+Guillain-+Barr\u00e9+Syndrome+in+Tasmania:+A+causal+link?&author=W.M.+Oo&author=P.+Giri&author=A.+de+Souza&volume=360&publication_year=2021&pages=577719&pmid=34560365&doi=10.1016/j.jneuroim.2021.577719&", "/pmc/articles/PMC8070856/", "https://pubmed.ncbi.nlm.nih.gov/33888484", "https://scholar.google.com/scholar_lookup?journal=ChAdOx1.+BMJ+Case+Rep&title=Guillain-Barre+syndrome+following+the+first+dose+of+the+chimpanzee+adenovirus-vectored+COVID-19+vaccine&author=S.U.+Patel&author=R.+Khurram&author=A.+Lakhani&author=B.+Quirk&volume=14&publication_year=2021&pages=1-5&", "/pmc/articles/PMC8462911/", "https://pubmed.ncbi.nlm.nih.gov/34567447", "//doi.org/10.1080%2F20009666.2021.1954284", "https://scholar.google.com/scholar_lookup?journal=J+Community+Hosp+Intern+Med+Perspect&title=A+case+of+Guillain\u2013Barre+syndrome+following+Pfizer+COVID-19+vaccine&author=S.J.+Rao&author=S.+Khurana&author=G.+Murthy&author=E.T.+Dawson&author=N.+Jazebi&volume=11&publication_year=2021&pages=597-600&pmid=34567447&doi=10.1080/20009666.2021.1954284&", "/pmc/articles/PMC8331323/", "https://pubmed.ncbi.nlm.nih.gov/34346014", "//doi.org/10.1007%2Fs10072-021-05523-5", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Guillain-Barr\u00e9+syndrome+following+BNT162b2+COVID-19+vaccine&author=M.+Trimboli&author=P.+Zoleo&author=G.+Arabia&author=A.+Gambardella&volume=42&publication_year=2021&pages=4401-4402&pmid=34346014&doi=10.1007/s10072-021-05523-5&", "https://pubmed.ncbi.nlm.nih.gov/34370408", "https://scholar.google.com/scholar_lookup?journal=Ideggyogy+Sz&title=A+variant+of+Guillain-Barre+syndrome+after+sars-cov-2+vaccination:+Amsan&author=N.K.+Tutar&author=T.+Eyig\u00fcrb\u00fcz&author=Z.+Yildirim&author=N.+Kale&volume=74&publication_year=2021&pages=286-288&pmid=34370408&", "/pmc/articles/PMC8285283/", "https://pubmed.ncbi.nlm.nih.gov/34272622", "//doi.org/10.1007%2Fs10072-021-05467-w", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=A+case+of+acute+demyelinating+polyradiculoneuropathy+with+bilateral+facial+palsy+after+ChAdOx1+nCoV-19+vaccine&author=N.+Alessandro&author=F.+de+Marchi&author=M.+Cecchin&author=I.+de+Paoli&author=S.+Onorato&volume=19&publication_year=2021&pages=4747-4749&doi=10.1007/s10072-021-05467-w&", "/pmc/articles/PMC8566211/", "https://pubmed.ncbi.nlm.nih.gov/34763263", "//doi.org/10.1016%2Fj.clinimag.2021.10.010", "https://scholar.google.com/scholar_lookup?journal=Clin+Imaging&title=Left+Bell's+palsy+following+the+first+dose+of+mRNA-1273+SARS-CoV-2+vaccine:+A+case+report&author=M.+Cellina&author=A.+D\u2019Arrigo&author=C.+Floridi&author=G.+Oliva&author=G.+Carrafiello&volume=82&publication_year=2022&pages=1-4&pmid=34763263&doi=10.1016/j.clinimag.2021.10.010&", "/pmc/articles/PMC8653229/", "https://pubmed.ncbi.nlm.nih.gov/34725821", "https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand&title=Multiple+cranial+nerve+palsies+following+COVID.+Case+report&author=M.M.+Manea&author=D.+Drago\u0219&author=I.+Enache&author=A.+George&author=S.+Tuta&volume=145&publication_year=2022&pages=257-259&pmid=34725821&", "/pmc/articles/PMC8318623/", "https://pubmed.ncbi.nlm.nih.gov/34322761", "//doi.org/10.1007%2Fs10072-021-05496-5", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Bell's+palsy+following+COVID-19+vaccination+with+high+CSF+antibody+response&author=M.+Obermann&author=M.+Krasniqi&author=N.+Ewers&author=J.+Fayad&author=U.+Haeberle&volume=42&publication_year=2021&pages=4397-4399&pmid=34322761&doi=10.1007/s10072-021-05496-5&", "/pmc/articles/PMC8649466/", "https://pubmed.ncbi.nlm.nih.gov/34816739", "https://scholar.google.com/scholar_lookup?journal=J+Int+Med+Res&title=Leg+paralysis+after+AstraZeneca+COVID-19+vaccination+diagnosed+as+neuralgic+amyotrophy+of+the+lumbosacral+plexus:+A+case+report&author=S.Il.+Kim&author=H.Y.+Seok&author=J.+Yi&volume=49&publication_year=2021&pages=1-5&", "/pmc/articles/PMC8250573/", "https://pubmed.ncbi.nlm.nih.gov/33890680", "https://scholar.google.com/scholar_lookup?journal=Muscle+Nerve&title=Parsonage+Turner+syndrome+after+COVID-19+vaccination&author=S.+Mahajan&author=F.+Zhang&author=A.+Mahajan&author=S.+Zimnowodzk&volume=64&publication_year=2021&pages=E3-E4&pmid=33890680&", "/pmc/articles/PMC8667016/", "https://pubmed.ncbi.nlm.nih.gov/34903275", "https://scholar.google.com/scholar_lookup?journal=J+Med+Case+Rep&title=Parsonage-Turner+syndrome+following+coronavirus+disease+2019+immunization+with+ChAdOx1-S+vaccine:+A+case+report+and+review+of+the+literature&author=B.K.+Vitturi&author=M.+Grandis&author=S.+Beltramini&author=A.+Orsi&author=A.+Schenone&volume=15&publication_year=2021&pages=589&pmid=34903275&", "/pmc/articles/PMC8319586/", "https://pubmed.ncbi.nlm.nih.gov/34324120", "//doi.org/10.1007%2Fs10072-021-05504-8", "https://scholar.google.com/scholar_lookup?journal=Neurol+Sci&title=Functional+neurological+disorder+after+COVID-19+vaccination&author=T.+Ercoli&author=L.+Lutzoni&author=G.+Orofino&author=A.+Muroni&author=G.+Defazio&volume=42&publication_year=2021&pages=3989-3990&pmid=34324120&doi=10.1007/s10072-021-05504-8&", "/pmc/articles/PMC8663753/", "https://pubmed.ncbi.nlm.nih.gov/34909338", "https://scholar.google.com/scholar_lookup?journal=Cureus&title=Oral+Herpes+Zoster+Infection+Following+COVID-19+Vaccination?:+A+Report+of+Five+Cases+Case+Presentation&author=H.+Fukuoka&author=N.+Fukuoka&author=T.+Kibe&author=R.S.+Tubbs&author=J.+Iwanaga&volume=13&publication_year=2021&pages=e19433&pmid=34909338&", "/pmc/articles/PMC8652627/", "https://pubmed.ncbi.nlm.nih.gov/34554601", "https://scholar.google.com/scholar_lookup?journal=Clin+Anat&title=A+narrative+review+and+clinical+anatomy+of+herpes+zoster+infection+following+COVID-19+vaccination&author=J.+Iwanaga&author=H.+Fukuoka&author=N.+Fukuoka&author=H.+Yutori&author=S.+Ibaragi&volume=35&publication_year=2022&pages=45-51&pmid=34554601&", "/pmc/articles/PMC9554338/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9554338%2F&text=Manifestaciones%20neurol%F3gicas%20asociadas%20a%20la%20vacuna%20contra%20COVID-19", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9554338%2F", "#", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}